Original Article
Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density
N Engl J Med 2002; 346:653-661February 28, 2002
- Abstract
Background
Bisphosphonates are effective agents for the management of osteoporosis. Their low bioavailability and low potency necessitate frequent administration on an empty stomach, which may reduce compliance. Gastrointestinal intolerance limits maximal dosing. Although intermittent intravenous treatments have been used, the optimal doses and dosing interval have not been systematically explored.
Methods
We studied the effects of five regimens of zoledronic acid, the most potent bisphosphonate, on bone turnover and density in 351 postmenopausal women with low bone mineral density in a one-year, randomized, double-blind, placebo-controlled trial. Women received placebo or intravenous zoledronic acid in doses of 0.25 mg, 0.5 mg, or 1 mg at three-month intervals. In addition, one group received a total annual dose of 4 mg as a single dose, and another received two doses of 2 mg each, six months apart. Lumbar-spine bone mineral density was the primary end point.
Results
There were similar increases in bone mineral density in all the zoledronic acid groups to values for the spine that were 4.3 to 5.1 percent higher than those in the placebo group (P<0.001) and values for the femoral neck that were 3.1 to 3.5 percent higher than those in the placebo group (P<0.001). Biochemical markers of bone resorption were significantly suppressed throughout the study in all zoledronic acid groups. Myalgia and pyrexia occurred more commonly in the zoledronic acid groups, but treatment-related dropout rates were similar to that in the placebo group.
Conclusions
Zoledronic acid infusions given at intervals of up to one year produce effects on bone turnover and bone density as great as those achieved with daily oral dosing with bisphosphonates with proven efficacy against fractures, suggesting that an annual infusion of zoledronic acid might be an effective treatment for postmenopausal osteoporosis.
Media in This Article
Figure 2
Effects of Various Regimens of Zoledronic Acid and Placebo on Biochemical Markers of Bone Resorption.Figure 1
Effects of Various Regimens of Zoledronic Acid and Placebo on Bone Mineral Density in the Lumbar Spine (Panel A) and the Femoral Neck (Panel B) in Postmenopausal Women with Low Bone Mineral Density.Article Activity
- Article
Oral bisphosphonates are widely used for treating osteoporosis and have been shown to increase bone mineral density and decrease the rate of fracture.1,2 However, they do have limitations related to long-term compliance, gastrointestinal intolerance, and poor and variable absorption from the gastrointestinal tract. Intermittent intravenous administration of bisphosphonates might address some of these problems and has been shown to be effective in the treatment of malignant hypercalcemia and Paget's disease and to reduce the rate of skeletal complications in patients with breast carcinoma or multiple myeloma. Evidence suggests that intravenous bisphosphonates increase bone mineral density in patients with osteoporosis, but most relevant studies have been small, unblinded, and short-term and have not systematically examined the effects of the dose and dosing interval on changes in bone mineral density and markers of bone turnover.3-6
Zoledronic acid is the most potent bisphosphonate that has been studied in clinical trials to date.7 It is superior to pamidronate in the treatment of cancer-related hypercalcemia.8 Because it has high potency, only small doses are required for the inhibition of bone resorption, and long dosing intervals may be used. We undertook a phase 2 study to examine the effect of intravenous zoledronic acid on bone density and bone turnover in postmenopausal women with low bone density and to assess the effects of varying the total dose administered and the dosing interval.
Methods
Study Subjects
A total of 351 postmenopausal women 45 to 80 years of age were studied at 24 centers in 10 countries. In all the women, menopause had occurred at least five years previously, either naturally or as the result of bilateral oophorectomy. All women had a bone mineral density at the lumbar spine (L1 to L4) that was at least 2.0 SD below the mean value for young adults (a T score lower than –2) and had no more than one vertebral fracture at screening. The date of onset of menopause was defined as the date of oophorectomy when applicable or as 12 months after the cessation of menses in women over 50 years of age and 18 months after the cessation of menses in women between 45 and 49 years of age. Major criteria for exclusion included systemic estrogen treatment within the previous three months, evidence of secondary osteoporosis, clinical or laboratory evidence of hepatic or renal disease, disorders of the parathyroid or thyroid glands, a serum 25-hydroxyvitamin D concentration of 15 ng per milliliter (37 nmol per liter) or less, a history of cancer, previous treatment with bisphosphonates or fluoride, and current therapy with any other drug known to affect the skeleton. The protocol was approved by the ethics committee at each center, and all the women gave written informed consent. Thirty-five women withdrew from the study, most commonly for personal reasons (in the case of 15 women) or because of adverse events (14 women). Thus, 316 women completed the study.
Treatment
All women received a calcium supplement (1 g per day). At study entry the women were randomly assigned to receive one of six treatment regimens in a double-blind fashion. Three groups received zoledronic acid by intravenous infusion every three months, one group at a dose of 0.25 mg, one at a dose of 0.5 mg, and one at a dose of 1 mg. Two other groups received a total dose of 4 mg of zoledronic acid — one group receiving a single 4-mg infusion at the beginning of the trial and the other group receiving two doses of 2 mg each, one at base line and the other at six months. Thus, there were three groups that received a total dose of 4 mg in one year. The sixth group received only placebo (saline). To maintain blinding, all women received an intravenous infusion of either zoledronic acid or placebo every three months. All infusions were 20 ml in volume and were infused over a period of five minutes. A dose of 4 mg given in this way produces a mean (±SD) peak serum concentration of zoledronic acid of 393±100 ng per milliliter. Infusions were prepared at each center by a pharmacist who had no contact with the patients and were labeled with the subject's study number and supplied to the study personnel.
Bone Density Measurement
The bone mineral density of the lumbar spine, the nondominant proximal femur and forearm, and the total body were measured by dual-energy x-ray absorptiometry at base line and at 6, 9, and 12 months with the use of Hologic QDR (Hologic, Waltham, Mass.) or Lunar (Madison, Wis.) instruments. Data were converted to Hologic-equivalent values by the method of Hui et al.9 A central laboratory (Institut für Funktionsanalyse, Hamburg, Germany) was responsible for the supervision of quality control for these measurements and notified investigators if any patient had a decrease in bone density of more than 5 percent from the base-line values.
Markers of Bone Turnover
Measurement of biochemical markers was performed in a central laboratory with the use of established methods. For serum bone-specific alkaline phosphatase, the Tandem-MP Ostase assay was used (Hybritech, Liege, Belgium). Serum osteocalcin was measured with the N-MID one-step enzyme-linked immunosorbent assay (Osteometer, Herlev, Denmark). Urinary type I collagen cross-linked N-telopeptide was measured with the Osteomark assay (Ostex, Seattle). Serum type I collagen C-telopeptide was measured with the CrossLaps assay (Osteometer).
Statistical Analysis
The necessary sample size was calculated as the number of patients needed to detect a difference between the zoledronic acid groups and the placebo group of at least 4 percent in the degree of change in lumbar-spine bone mineral density from base line to 12 months. Bonferroni's correction was used to adjust for multiple comparisons in order to ensure an overall nominal significance level of 0.05. Given a noncentral t distribution with a type I error of 0.025, a power of 80 percent, a two-sided alternative, and a standard deviation of 5.7 percent, we calculated that 40 patients were needed in each treatment group in order to allow detection of a difference of 4 percent. To allow for a possible 15 percent dropout rate, a total sample size of 290 was selected.
All analyses were performed according to the intention-to-treat principle with the use of all available data from all patients who received study drug. Missing values were not imputed or replaced. Analysis of covariance was performed (with the Proc Mixed procedure of SAS software [SAS Institute, Cary, N.C.]) to estimate differences between the treatment groups. The statistical fixed-effects model considered center and treatment as main variables. In addition, the base-line values, if measured, were used as covariates. The analyses were repeated with the last observation carried forward and produced essentially the same results (data not shown).
For the primary variable, adjustment for multiple comparisons between placebo and the active doses of zoledronic acid was performed at a one-sided alpha level of 0.025, according to the method of Marcus et al.10 For secondary variables, pairwise comparisons were investigated in the exploratory analysis (unadjusted for multiple comparisons). The pairwise comparisons were tested at a two-sided level of significance of 0.05. In addition to the P value for the comparisons between treatment groups, estimates of the differences and associated 95 percent confidence intervals were calculated.
The protocol was designed and developed by the sponsor and submitted to the investigators for comments and amendments. The final protocol was then accepted by the investigators and submitted to the ethics review committees of their institutions for approval. Data management and statistical analysis were performed by the sponsor. Interpretation of the data and preparation of the manuscript were performed by a publication committee that included three academic researchers who were investigators in the trial (Drs. Reid, Brown, and Burckhardt) and Dr. Trechsel, the author of the study protocol, as a representative of the sponsor. These authors had full and unfettered access to the data and take full responsibility for the completeness and accuracy of the reported data. The study sponsor placed no limits on statements made in the final paper.
Results
Study Subjects
The base-line characteristics of the women who participated in the study are summarized in Table 1Table 1
Base-Line Characteristics.. All but two women were white, and none had vertebral fractures at study entry.Bone Mineral Density
Mean bone-mineral-density values in the lumbar spine corresponded to a T score of –2.9. All groups receiving zoledronic acid regimens had a progressive increase in bone mineral density in the lumbar spine throughout the 12-month study period, although the rate of increase tended to slow in the second half of the study (Figure 1AFigure 1
Effects of Various Regimens of Zoledronic Acid and Placebo on Bone Mineral Density in the Lumbar Spine (Panel A) and the Femoral Neck (Panel B) in Postmenopausal Women with Low Bone Mineral Density.). Throughout the study, the values for lumbar-spine bone mineral density achieved with all zoledronic acid regimens were significantly higher than those in the placebo group (P<0.001), and there were no significant differences among the zoledronic acid groups. At 12 months, the mean lumbar-spine bone mineral density in the groups receiving zoledronic acid was 4.3 to 5.1 percent higher than the mean value in the placebo group, which remained stable. The bone mineral density in the femoral neck also increased progressively throughout the study period; all zoledronic acid groups had similar increases to values that were significantly higher than those in the placebo group (differences of 3.1 to 3.5 percent at 12 months, P<0.001) (Figure 1B). The femoral-neck bone mineral density declined by 0.4 percent in the placebo group.Bone mineral density at the distal radius responded to zoledronic acid treatment to a lesser extent, resulting in differences from the placebo group of 0.8 to 1.6 percent at 12 months (data not shown); in the placebo group, distal radial bone mineral density decreased by 0.8 percent. All zoledronic acid regimens except the four doses of 0.25 mg each resulted in distal radial bone mineral density that was significantly greater than that in the placebo group (P≤0.05 for all comparisons). The results for total-body bone mineral density were similar (data not shown). At 12 months, the differences in total-body bone mineral density between the zoledronic acid groups and the placebo group ranged from 0.9 percent to 1.3 percent and were significant (P<0.03 for all comparisons) for all regimens except the four doses of 0.5 mg each.
Markers of Bone Turnover
Markers of bone resorption reached a nadir at one month (median decreases of 65 to 83 percent in serum C-telopeptide and 50 to 69 percent in the urinary N-telopeptide:creatinine ratio), whereas there were no significant changes in the placebo group (Figure 2Figure 2
Effects of Various Regimens of Zoledronic Acid and Placebo on Biochemical Markers of Bone Resorption.). The decrease in markers of resorption tended to be dose-dependent, particularly at three months — a pattern that is consistent with previous reports that higher doses of bisphosphonates increase the duration of action of the drug.11 We do not have full documentation of the immediate reductions in bone resorption after each infusion, because most samples were obtained only every three months. The suppression of resorption was maintained at 12 months. At 12 months, the zoledronic acid regimens were associated with decreases of 49 to 52 percent in serum C-telopeptide (as compared with a decrease of 8 percent in the placebo group) and decreases of 54 to 65 percent in the ratio of urinary N-telopeptide to creatinine (as compared with an increase of 3 percent in the placebo group). All zoledronic acid groups had values for these markers of resorption that were significantly different from those in the placebo group (P<0.01 for all comparisons), but there were no significant differences among the zoledronic acid groups. Bone-specific alkaline phosphatase and osteocalcin, which are serum markers of bone formation, showed similar responses, but there was no sharp decrease apparent at one month (Figure 3Figure 3
Effects of Various Regimens of Zoledronic Acid and Placebo on Serum Markers of Bone Formation.). Again, suppression persisted at 12 months with all doses (P<0.001).Bone Biopsies
A 7.5-mm transiliac biopsy specimen was obtained from 43 women and double-labeled with tetracycline. Of these specimens, 27 were complete and suitable for histomorphometric analysis. The sections were undecalcified and stained with Goldner's trichrome, except for tetracycline measurements, which were made on unstained sections. Women treated with zoledronic acid at any dose had significantly lower proportions of mineralizing surfaces, rates of bone formation, adjusted mineral apposition rates, and activation frequencies than the women in the placebo group (differences of 71 percent to 84 percent, P<0.05); there were nonsignificant differences in the proportion of eroded surface (39 percent lower than that in the placebo group, P<0.06) and in eroded volume (48 percent lower, P<0.07). No change was noted in cortical bone thickness or porosity; cancellous bone volume; trabecular thickness, separation, or number; wall width of trabecular bone packets; number of nodes per volume of tissue; or osteoid maturation time. No dose effect was found with respect to any of these factors. No evidence of osteomalacia was found, either by qualitative assessment or on the basis of such quantitative measures as osteoid thickness and volume or the mineral apposition rate. No other qualitative abnormalities were apparent.
Fractures
Spinal radiographs at base line and one year showed no vertebral fractures during the study. No nonvertebral fractures occurred in the group receiving four doses of 0.25 mg of zoledronic acid; two nonvertebral fractures occurred in the group receiving four doses of 1 mg of zoledronic acid; and one nonvertebral fracture occurred in each of the other groups.
Safety
Mean serum calcium concentrations in the zoledronic acid groups declined significantly (P<0.05 for all comparisons), by approximately 0.08 mmol per liter, between base line and one month but were similar to those in the placebo group from three months onward. Serum phosphate concentrations in the zoledronic acid groups had decreased by 0.06 to 0.12 mmol per liter at one month and generally remained about 0.05 mmol per liter below those in the placebo group throughout the study period, although they did not differ significantly from those in the placebo group at one year. Intact parathyroid hormone was measured in serum at base line and 12 months. There were no significant differences among the groups at the 12-month follow-up, although the mean value was about 30 percent higher than the base-line value in the women in the group receiving four doses of 1 mg of zoledronic acid, possibly because sampling was performed only three months after the last dose had been administered in this group.
The rates of adverse events were similar in all the active-treatment groups (Table 2Table 2
Adverse Events.). However, treatment-related adverse events were significantly more common in the zoledronic acid groups than in the placebo group (rates of 45 to 67 percent vs. 27 percent; data not shown). In the zoledronic acid groups, most adverse events were instances of musculoskeletal pain, nausea, or fever, most of which were rated as mild. Most occurred the first time the drug was administered. Five women withdrew from the study because of drug-related adverse events, all of which were reactions after the first infusion of zoledronic acid. These withdrawals were not dose-related; two occurred in women who were receiving the lowest dose and two in women receiving the highest dose. There was no evidence of adverse effects on renal function with any of these regimens. Overall, the proportions of women who withdrew from the study because of adverse events were similar in all groups. Symptoms at the infusion site were uncommon in all groups (e.g., reported in no patients receiving a single 4-mg dose of zoledronic acid and in two patients receiving placebo). Iritis did not develop in any patients, and the occurrence of any eye disorder was uncommon (e.g., reported in two patients receiving a single 4-mg dose of zoledronic acid and in nine patients receiving placebo).Discussion
Intermittent intravenous administration of the potent bisphosphonate zoledronic acid results in changes in biochemical markers of bone turnover and in bone mineral density that are similar to those observed with daily oral bisphosphonate therapy. Thus, the reductions in markers at one year in the present study are similar to those seen with 5 mg of risedronate per day,12 2.5 to 5 mg of ibandronate per day,13 and 10 mg of alendronate per day.14-16 Zoledronic acid increases spinal bone mineral density at 12 months to 5 percent above values found in patients receiving placebo — an increase similar to that achieved with a daily 10-mg dose of alendronate (5 percent),17 a daily 5-mg dose of risedronate (3 percent),12 or a daily 150-mg dose of pamidronate (5 percent).18 Intravenous zoledronic acid also produced results similar to those of the oral regimens at the femoral neck (alendronate, 3 percent increase in bone density; risedronate, 2 percent; pamidronate, 3 percent) and in the total body (alendronate, 1.5 percent increase; pamidronate, 1 percent).
Our study assessed longer intervals between doses than have been assessed by previous studies of intermittent bisphosphonate therapy. Etidronate has been used for many years in two-week oral courses administered at three-month intervals.19,20 There is also evidence that intravenous pamidronate3 or ibandronate,4 given every three months, has beneficial effects on bone density in women with postmenopausal osteoporosis. The disappointing data on fractures from a recent study of intermittent ibandronate therapy (1 mg intravenously every three months)21 has been interpreted as indicating that a dosing interval of three months is too long. However, this ibandronate regimen did not stably suppress markers of bone resorption; a substantial maximal suppression of C-telopeptide excretion (by 50 percent) was rapidly offset, so that the level before the next dose was only 10 to 20 percent below that in the placebo group.4 As a result, the changes in bone density (increases of 2.9 percent in the spine at 12 months4 or to 4 percent higher than the spinal bone mineral density in the placebo group at 3 years21) were smaller than those found in our study; this effect is consistent with the moderate effect of this dose of ibandronate on the incidence of vertebral fracture (a 26 percent reduction at 3 years). Our data indicate that much longer dosing intervals are compatible with efficacy (in terms of both suppression of bone turnover and increase in bone density) if the dose of bisphosphonate is sufficiently large. Indeed, the present study does not establish a maximal dosing interval, since turnover remained suppressed at 12 months. Thus, it is possible that a longer interval between doses could be effective, particularly if larger doses of zoledronic acid were used.
How a single infusion of zoledronic acid suppresses bone turnover for so long remains to be determined. Prolonged suppression is not the result of the persistence of the drug in the circulation, given that by 24 hours after administration, drug levels are less than 1 percent of the postadministration peak and 40 percent of the dose has been excreted in the urine. The balance of the dose is presumably bound to bone and is slowly released back into the circulation, giving rise to a 167-hour terminal half-life in plasma. It has been thought that bisphosphonates are located exclusively on osteoclastic surfaces22 and that short-term exposure inhibits activity in a single generation of basic multicellular units in bone. The life span of the basic multicellular unit (about three months) then determines the duration of action of the drug. However, evidence suggests that bisphosphonates are also deposited on osteoblastic and resting bone surfaces and remain there for the long term.23 The existence of such deposits would provide a possible explanation for our results, since residue from a single dose could interfere with the future development of basic multicellular units at these surfaces. It is also possible that direct effects on existing basic multicellular units and osteocytes24,25 result in reduced formation of succeeding basic multicellular units.
Zoledronic acid was generally well tolerated, and the rate of retention of subjects in the study was high. The adverse events that were more common in women receiving zoledronic acid are those that have occurred previously in patients receiving intravenous aminobisphosphonates and are transient. Infrequent doses may increase tolerance of these side effects.
The inclusion of a placebo group in this study permits quantification of the size of the therapeutic effect and facilitates comparison of the present data with those from other studies. We believe this use of a placebo is ethical, since the bone density used as a criterion for entry (a T score of less than –2) is higher than that required at the participating centers for a diagnosis of osteoporosis and would certainly not be considered to be a threshold for therapeutic intervention at these centers. Thus, the study was conducted in a low-risk population — a characterization supported by the fact that no spinal fractures occurred during the study period. Only one sixth of these low-risk subjects received placebo, and they received it for a maximum of 12 months, after which all women received active therapy.
Osteoporosis has been regarded as requiring daily therapy, and maintaining compliance with daily regimens for a predominantly asymptomatic condition has been a major problem.26,27 Administration of treatment at intervals of 6 to 12 months or more is likely to be much more acceptable to patients and could reduce costs. A greater proportion of the at-risk population might take advantage of prophylaxis against osteoporosis if an intermittent regimen were used, and the rate of fractures might therefore decrease. However, studies that demonstrate an effect on the rate of fractures are needed before any recommendation can be made.
Supported by a grant from Novartis Pharma.
We are indebted to Esther Hagin of Novartis Pharma, Basel, Switzerland, for her expert work in conducting the trial.
Source Information
From the Department of Medicine, University of Auckland, Auckland, New Zealand (I.R.R.); the Centre de Recherche du Centre Hospitalier del Université Laval, Quebec, Que., Canada (J.P.B.); the Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (P.B.); Novartis Pharmaceuticals, East Hanover, N.J. (Z.H., P.R.); Novartis Pharma, Basel, Switzerland (U.T., A.W.); the Department of Rheumatology, Université Catholique de Louvain, St. Luc, Brussels, Belgium (J.-P.D.); the Department of Endocrinology, University Hospital of Ghent, Ghent, Belgium (J.-M.K.); the Medizinische Universitätspoliklinik, Inselspital Bern, Bern, Switzerland (P.J.); the Endocrinology and Supportive Care Clinic, Institut J. Bordet, Free University of Brussels, Brussels, Belgium (J.-J.B.); and the Department of Rheumatology and Bone Diseases, Hôpital Edouard Herriot, Lyons, France (P.J.M.).
Address reprint requests to Professor Reid at the Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand, or at i.reid@auckland.ac.nz.
Other authors were Maria Luisa Brandi, M.D., Unità di Endocrinologia, Ospedale di Careggi, Florence, Italy; Johann Broell, M.D., Medizinische Abteilung mit Rheumatologie und Osteologie, Kaiser-Franz-Josef-Spital der Stadt Wien, Vienna, Austria; Raffaele Di Micco, M.D., Centro di Fisiopatologia della Menopausa, Ospedale Maggiore La Maternità, Bologna, Italy; Andrea Riccardo Genazzani, M.D., Ospedali Riuniti S. Chiara, Pisa, Italy; Dieter Felsenberg, M.D., Universitätsklinikum Benjamin Franklin, Strahlenklinik und Poliklinik, Berlin, Germany; Joachim Happ, M.D., Frankfurt, Germany; Michael J. Hooper, F.R.A.C.P., Department of Endocrinology, Concord Hospital, Concord, N.S.W., Australia; Jochen Ittner, M.D., Augsburg, Germany; Georg Leb, M.D., Klinische Abteilung für Endokrinologie und Nuklearmedizin, Medizinische Universitätsklinik, Graz, Austria; Hans Mallmin, M.D., Ph.D., Medicinkliniken, Akademisca Sjukhuset, Uppsala, Sweden; Timothy Murray, M.D., Metabolic Bone Clinic, St. Michael's Hospital, Toronto; Sergio Ortolani, M.D., Centro Studi Metabolismo Osseo, Istituto Auxologico Italiano, Milan, Italy; Alessandro Rubinacci, M.D., Unità Metabolica dell'Osso, Ospedale S. Raffaele, Milan, Italy; Maria Sääf, M.D., Ph.D., Endokrinologiska Kliniken, Karolinska Sjukhuset, Stockholm, Sweden; Goran Samsioe, M.D., Ph.D., Kvinnokliniken, Universitetskliniken, Lund, Sweden; and Leon Verbruggen, M.D., Ph.D., Department of Rheumatology, Academic Hospital, Brussels Free University, Brussels, Belgium.
- References
References
1
Black DM ,Cummings SR ,Karpf DB , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-1541
CrossRef | Web of Science | Medline2
McClung MR ,Geusens P ,Miller PD , et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-340
Full Text | Web of Science | Medline3
Thiebaud D ,Burckhardt P ,Melchior J , et al. Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporos Int 1994;4:76-83
CrossRef | Web of Science | Medline4
Thiebaud D ,Burckhardt P ,Kriegbaum H , et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997;103:298-307
CrossRef | Web of Science | Medline5
Khan SA ,Kanis JA ,Vasikaran S , et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 1997;12:1700-1707
CrossRef | Web of Science | Medline6
Passeri M ,Baroni MC ,Pedrazzoni M , et al. Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis. Bone Miner 1991;15:237-247
CrossRef | Medline7
Body JJ ,Lortholary A ,Romieu G ,Vigneron AM ,Ford J . A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 1999;14:1557-1561
CrossRef | Web of Science | Medline8
Major P ,Lortholary A ,Hon J , et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19:558-567
Web of Science | Medline9
Hui SL ,Gao SJ ,Zhou XH , et al. Universal standardization of bone density measurements: a method with optimal properties for calibration among several instruments. J Bone Miner Res 1997;12:1463-1470
CrossRef | Web of Science | Medline10
Marcus R ,Peritz E ,Gabriel KR . On closed testing procedures with special reference to ordered analysis of variance. Biometrika 1976;63:655-660
CrossRef | Web of Science11
Thiebaud D ,Husi B ,Jacquet AF ,Burckhardt P . Effects of ibandronate i.v. bolus injection in healthy men and postmenopausal women. J Bone Miner Res 1997;12:Suppl 1:S343-S343 abstract.
CrossRef | Web of Science12
Harris ST ,Watts NB ,Genant HK , et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999;282:1344-1352
CrossRef | Web of Science | Medline13
Ravn P ,Clemmesen B ,Riis BJ ,Christiansen C . The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone 1996;19:527-533
CrossRef | Web of Science | Medline14
Garnero P ,Shih WCJ ,Gineyts E ,Karpf DB ,Delmas PD . Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693-1700
CrossRef | Web of Science | Medline15
Devogelaer JP ,Broll H ,Correa-Rotter R , et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 1996;18:141-150[Erratum, Bone 1996;19:78.]
CrossRef | Web of Science | Medline16
Chesnut CH III ,McClung MR ,Ensrud KE , et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995;99:144-152
CrossRef | Web of Science | Medline17
Liberman UA ,Weiss SR ,Broll J , et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-1443
Full Text | Web of Science | Medline18
Reid IR ,Wattie DJ ,Evans MC ,Gamble GD ,Stapleton JP ,Cornish J . Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab 1994;79:1595-1599
CrossRef | Web of Science | Medline19
Storm T ,Thamsborg G ,Steiniche T ,Genant HK ,Sorensen OH . Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265-1271
Full Text | Web of Science | Medline20
Watts NB ,Harris ST ,Genant HK , et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73-79
Full Text | Web of Science | Medline21
Recker RR ,Stakkestad JA ,Felsenberg D , et al. A new treatment paradigm: quarterly injections of ibandronate reduce the risk of fractures in women with postmenopausal osteoporosis (PMO): results of a 3-year trial. Osteoporos Int 2000;11:Suppl 2:S209-S209 abstract.
Web of Science22
Sato M ,Grasser W ,Endo N , et al. Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88:2095-2105
CrossRef | Web of Science | Medline23
Masarachia P ,Weinreb M ,Balena R ,Rodan GA . Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 1996;19:281-290
CrossRef | Web of Science | Medline24
Reinholz GG ,Getz B ,Pederson L , et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 2000;60:6001-6007
Web of Science | Medline25
Plotkin LI ,Weinstein RS ,Parfitt AM ,Roberson PK ,Manolagas SC ,Bellido T . Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999;104:1363-1374
CrossRef | Web of Science | Medline26
Faulkner DL ,Young C ,Hutchins D ,McCollam JS . Patient noncompliance with hormone replacement therapy: a nationwide estimate using a large prescription claims database. Menopause 1998;5:226-229
Web of Science | Medline27
Christensen PM ,Kristiansen IS ,Brosen K ,Brixen K ,Abrahamsen B ,Andersen M . Compliance to bisphosphonates -- a population-based study using a drug prescription database. Bone 2000;27:Suppl:21S-21S abstract.
CrossRef
- Citing Articles (343)
Citing Articles
1
Shunji Takahashi, Takuji Iwase, Norio Kohno, Takashi Ishikawa, Tetsuya Taguchi, Masato Takahashi, Jun Horiguchi, Seigo Nakamura, Yasuo Hozumi, Masao Fukunaga, Shinzaburo Noguchi. (2012) Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results. Breast Cancer Research and Treatment
CrossRef2
Pawel Szulc. (2012) The role of bone turnover markers in monitoring treatment in postmenopausal osteoporosis. Clinical Biochemistry
CrossRef3
J.-H. Kang, J. J. Keller, H.-C. Lin. (2012) A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke. Osteoporosis International
CrossRef4
Hai NIE, Chao PENG, Jie HAO, Zhen-ming HU, Hong AN. (2011) Zoledronic acid in preventing fractures in women with postmenopausal osteoporosis: a meta analysis. Academic Journal of Second Military Medical University 31:9, 985-990
CrossRef5
Jelena S Rudic, Vanja Giljaca, Miodrag N Krstic, Goran Bjelakovic, Christian Gluud, Jelena S Rudic. 2011. Bisphosphonates for osteoporosis in primary biliary cirrhosis. .
CrossRef6
Hui-Hui Tan, Paul Martin. (2011) Care of the Liver Transplant Candidate. Clinics in Liver Disease 15:4, 779-806
CrossRef7
Karen Tipples, Anne Robinson. (2011) Optimal Management of Cancer Treatment-Induced Bone Loss. Drugs & Aging 28:11, 867-883
CrossRef8
Jacqueline G. Garrison, Joshua A. Gargac, Glen L. Niebur. (2011) Shear strength and toughness of trabecular bone are more sensitive to density than damage. Journal of Biomechanics 44:16, 2747-2754
CrossRef9
Jillian Cornish, Usha Bava, Karen E. Callon, Jizhong Bai, Dorit Naot, Ian R. Reid. (2011) Bone-bound bisphosphonate inhibits growth of adjacent non-bone cells. Bone 49:4, 710-716
CrossRef10
Brian J Rebolledo, Aasis Unnanuntana, Joseph M Lane. (2011) A Comprehensive Approach to Fragility Fractures. Journal of Orthopaedic Trauma 25:9, 566-573
CrossRef11
Enrique Casado Burgos. (2011) Nuevos datos sobre el tratamiento con bisfosfonatos: ¿son aconsejables unas vacaciones terapéuticas?. Reumatología Clínica 7, 28-33
CrossRef12
Jacques P. Brown, J.D. Adachi, D.L. Kendler, R. Rigal, G. Deutsch, J.M. Leclerc. (2011) A community-based clinical trial of Intra-Venous zOledRonic acid once Yearly in comparison to oral bisphosphonates in postmenopausal women with osteoporosis: The IVORY trial. Contemporary Clinical Trials 32:5, 741-746
CrossRef13
N. Guañabens, A. Monegal, A. Muxi, A. Martinez-Ferrer, R. Reyes, J. Caballería, L. Río, P. Peris, F. Pons, A. Parés. (2011) Patients with cirrhosis and ascites have false values of bone density. Osteoporosis International
CrossRef14
Julie LI-YU, Emmanuel C. PEREZ, Arturo CAÑETE, Lauro BONIFACIO, Lyndon Q. LLAMADO, Romil MARTINEZ, Allan LANZON, Mae SISON, . (2011) Consensus statements on osteoporosis diagnosis, prevention, and management in the Philippines. International Journal of Rheumatic Diseases 14:3, 223-238
CrossRef15
Ewa Sewerynek. (2011) Bisphosphonates and the risk of atrial fibrillation in elderly women with osteoporosis. Aging Health 7:4, 585-589
CrossRef16
James R. Berenson, Ori Yellin, Albert Quiery, James Brady, Ravi Patel, Siu-Fun Wong, Donald Colbourn, Donald Gravenor, Natasha Tiffany, H.K. Shamasunder, Benjamin Waterman, Kathryn Melamed, Eric Wirtschafter. (2011) A Retrospective Study to Evaluate the Work-up and Follow-up of Patients With Monoclonal Gammopathy of Undetermined Significance. Clinical Lymphoma Myeloma and Leukemia 11:4, 336-341
CrossRef17
Maurizio Rossini, Ombretta Viapiana, Banu Kalpakcioglu, Rajoo Dhangana, Davide Gatti, Vania Braga, Elena Fracassi, Silvano Adami. (2011) Long-Term Effects of Neridronate and its Discontinuation in Patients with Primary Hyperparathyroidism. Calcified Tissue International 89:1, 21-28
CrossRef18
R. Graham G. Russell. (2011) Bisphosphonates: The first 40years. Bone 49:1, 2-19
CrossRef19
Richard Eastell, Jennifer S. Walsh, Nelson B. Watts, Ethel Siris. (2011) Bisphosphonates for postmenopausal osteoporosis. Bone 49:1, 82-88
CrossRef20
Ufuk Tatlı, Yakup Üstün, Mehmet Kürkçü, Özgür Erdoğan, Cihan Cem Gürbüz, Hülya Özgür, Sait Polat. (2011) Effects of Zoledronic Acid on Healing of Mandibular Fractures: An Experimental Study in Rabbits. Journal of Oral and Maxillofacial Surgery 69:6, 1726-1735
CrossRef21
Jelena S Rudic, Vanja Giljaca, Miodrag N Krstic, Goran Bjelakovic, Christian Gluud, Jelena S Rudic. 2011. Bisphosphonates for osteoporosis in primary biliary cirrhosis. .
CrossRef22
Jawl-Shan Hwang, Lin-Show Chin, Jung-Fu Chen, Tzay-Shing Yang, Po-Quang Chen, Keh-Sung Tsai, Ping Chung Leung. (2011) The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis. Journal of Bone and Mineral Metabolism 29:3, 328-333
CrossRef23
E. Seeman. (2011) Anabolic Plus Antiresorptive: Is One Plus One More or Less Two?. IBMS BoneKEy 8:5, 221-228
CrossRef24
Jochen Klaus, M M Haenle, C Schröter, G Adler, G von Boyen, M Reinshagen, C von Tirpitz. (2011) A Single Dose of Intravenous Zoledronate Prevents Glucocorticoid Therapy-Associated Bone Loss in Acute Flare of Crohn's Disease, a Randomized Controlled Trial. The American Journal of Gastroenterology 106:4, 786-793
CrossRef25
F. Ozturk, H. Babacan, C. Gumus. (2011) Effects of zoledronic acid on sutural bone formation: a computed tomography study. The European Journal of Orthodontics
CrossRef26
S. Lee, P. Glendenning, C. A. Inderjeeth. (2011) Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporosis International 22:3, 741-753
CrossRef27
Jean-Baptiste Lattouf, Hicham Fadlallah, Fred Saad. (2011) Androgen Deprivation and Bone. Current Osteoporosis Reports 9:1, 20-24
CrossRef28
Jennifer M Grossman. (2011) Osteoporosis prevention. Current Opinion in Rheumatology 23:2, 203-210
CrossRef29
Orlaith Brennan, Oran D. Kennedy, T. Clive Lee, Susan M. Rackard, Fergal J. O'Brien. (2011) Effects of estrogen deficiency and bisphosphonate therapy on osteocyte viability and microdamage accumulation in an ovine model of osteoporosis. Journal of Orthopaedic Research 29:3, 419-424
CrossRef30
S. J. Craig, P. P. Youssef, J. H. Vaile, L. Sullivan, J. F. Bleasel. (2011) Intravenous zoledronic acid and oral alendronate in patients with a low trauma fracture: experience from an osteoporosis clinic. Internal Medicine Journal 41:2, 186-190
CrossRef31
O. Brennan, O.D. Kennedy, T.C. Lee, S.M. Rackard, F.J. O’Brien, L.M. McNamara. (2011) The effects of estrogen deficiency and bisphosphonate treatment on tissue mineralisation and stiffness in an ovine model of osteoporosis. Journal of Biomechanics 44:3, 386-390
CrossRef32
Socrates E. Papapoulos. (2011) Use of bisphosphonates in the management of postmenopausal osteoporosis. Annals of the New York Academy of Sciences 1218:1, 15-32
CrossRef33
J. S. Bubbear, A. Gall, F. R. I. Middleton, M. Ferguson-Pell, R. Swaminathan, R. W. Keen. (2011) Early treatment with zoledronic acid prevents bone loss at the hip following acute spinal cord injury. Osteoporosis International 22:1, 271-279
CrossRef34
Sonja Gamsjaeger, Birgit Buchinger, Elizabeth Zwettler, Robert Recker, Dennis Black, Juerg A Gasser, Erik F Eriksen, Klaus Klaushofer, Eleftherios P Paschalis. (2011) Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid. Journal of Bone and Mineral Research 26:1, 12-18
CrossRef35
Jang-Jaer Lee, Shih-Jung Cheng, Yi-Ping Wang, Jiiang-Huei Jeng, Chun-Pin Chiang, Sang-Heng Kok. (2011) Osteonecrosis of the jaws associated with the use of yearly zoledronic acid: Report of 2 cases. Head & Neckn/a-n/a
CrossRef36
Hyosook Hwang, Sharon L Hale, Justin Leeka, Robert A Kloner. (2010) Effects of Zoledronate in the Repair of Chronically Infarcted Rat Myocardium. Journal of Cardiovascular Pharmacology 56:6, 604-609
CrossRef37
Romina Ruscica, Micaela Bianchi, Mariano Quintero, Andrea Martinez, Daniel R. Vega. (2010) Solid-state forms of zoledronic acid: Polymorphism in hydrates. Journal of Pharmaceutical Sciences 99:12, 4962-4972
CrossRef38
Patricia A. Howard, Brian J. Barnes, James L. Vacek, Warren Chen, Sue-Min Lai. (2010) Impact of Bisphosphonates on the Risk of Atrial Fibrillation. American Journal Cardiovascular Drugs 10:6, 359-367
CrossRef39
Douglas A. Johnson, Melissa I. Williams, Valentina I. Petkov, Robert A. Adler. (2010) Zoledronic Acid Treatment of Osteoporosis: Effects in Men. Endocrine Practice 16:6, 960-967
CrossRef40
, E. Noon, S. Singh, J. Cuzick, T. D. Spector, F. M. K. Williams, M. L. Frost, A. Howell, M. Harvie, R. Eastell, R. E. Coleman, I. Fogelman, G. M. Blake. (2010) Significant differences in UK and US female bone density reference ranges. Osteoporosis International 21:11, 1871-1880
CrossRef41
Michael Maricic. (2010) The role of zoledronic acid in the management of osteoporosis. Clinical Rheumatology 29:10, 1079-1084
CrossRef42
J.-J. Body, P. Bergmann, S. Boonen, Y. Boutsen, J.-P. Devogelaer, S. Goemaere, J.-M. Kaufman, S. Rozenberg, J.-Y. Reginster. (2010) Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporosis International 21:10, 1657-1680
CrossRef43
Anne Marie Sbrocchi, Sylviane Forget, Diane Laforte, E. Michel Azouz, Celia Rodd. (2010) Zoledronic acid for the treatment of osteopenia in pediatric Crohn's disease. Pediatrics International 52:5, 754-761
CrossRef44
Andrew Grey, Mark Bolland, Diana Wattie, Anne Horne, Greg Gamble, Ian R Reid. (2010) Prolonged antiresorptive activity of zoledronate: A randomized, controlled trial. Journal of Bone and Mineral Research 25:10, 2251-2255
CrossRef45
David M. Reid. (2010) Update on the Use of Zoledronic Acid in the Management of Osteoporosis. Current Osteoporosis Reports 8:3, 145-150
CrossRef46
Santiago Palacios. (2010) Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis. Current Medical Research and Opinion 26:7, 1553-1563
CrossRef47
Rohit Bhuriya, Mukesh Singh, Janos Molnar, Rohit Arora, Sandeep Khosla. (2010) Bisphosphonate use in women and the risk of atrial fibrillation: A systematic review and meta-analysis. International Journal of Cardiology 142:3, 213-217
CrossRef48
Inusha Panigrahi, Rashmi Ranjan Das, Sheetal Sharda, Ram Kumar Marwaha, Niranjan Khandelwal. (2010) Response to zolendronic acid in children with type III osteogenesis imperfecta. Journal of Bone and Mineral Metabolism 28:4, 451-455
CrossRef49
Yanming Bi, Yamei Gao, Driss Ehirchiou, Chunzhang Cao, Takashi Kikuiri, Anh Le, Songtao Shi, Li Zhang. (2010) Bisphosphonates Cause Osteonecrosis of the Jaw-Like Disease in Mice. The American Journal of Pathology 177:1, 280-290
CrossRef50
Takashi Kikuiri, Insoo Kim, Takyoshi Yamaza, Kentaro Akiyama, Qunzhou Zhang, Yunsheng Li, Chider Chen, WanJun Chen, Songlin Wang, Anh D Le, Songtao Shi. (2010) Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice. Journal of Bone and Mineral Research 25:7, 1668-1679
CrossRef51
Anna D. Petropoulou, Raphael Porcher, Andrée-Laure Herr, Agnès Devergie, Thomas Funck Brentano, Patricia Ribaud, Fernando O. Pinto, Vanderson Rocha, Régis Peffault de Latour, Philippe Orcel, Gérard Socié, Marie Robin. (2010) Prospective Assessment of Bone Turnover and Clinical Bone Diseases After Allogeneic Hematopoietic Stem-Cell Transplantation. Transplantation 89:11, 1354-1361
CrossRef52
Jean-Baptiste Lattouf, Fred Saad. (2010) Bone complications of androgen deprivation therapy: screening, prevention, and treatment. Current Opinion in Urology 20:3, 247-252
CrossRef53
Rebecca Aft, Michael Naughton, Kathryn Trinkaus, Mark Watson, Lourdes Ylagan, Mariana Chavez-MacGregor, Jing Zhai, Sacha Kuo, William Shannon, Kathryn Diemer, Virginia Herrmann, Jill Dietz, Amjad Ali, Matthew Ellis, Peter Weiss, Timothy Eberlein, Cynthia Ma, Paula M Fracasso, Imran Zoberi, Marie Taylor, William Gillanders, Timothy Pluard, Joanne Mortimer, Katherine Weilbaecher. (2010) Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. The Lancet Oncology 11:5, 421-428
CrossRef54
Vivek K. Wadhwa, Robin Weston, Nigel J. Parr. (2010) Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer. BJU International 105:8, 1082-1088
CrossRef55
M. M. Wilkes, R. J. Navickis, W. W. Chan, E. M. Lewiecki. (2010) Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials. Osteoporosis International 21:4, 679-688
CrossRef56
Stephanie L. Hines, Jeff A. Sloan, Pamela J. Atherton, Edith A. Perez, Shaker R. Dakhil, David B. Johnson, Pavan S. Reddy, Robert J. Dalton, Bassam I. Mattar, Charles L. Loprinzi. (2010) Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. The Breast 19:2, 92-96
CrossRef57
Teun M. Post, Serge C.L.M. Cremers, Thomas Kerbusch, Meindert Danhof. (2010) Bone Physiology, Disease and Treatment. Clinical Pharmacokinetics 49:2, 89-118
CrossRef58
Jeffrey A. Dodge, Henry U. Bryant. 2010. Osteoporosis Therapy: Mechanistic Antiresorptives. .
CrossRef59
Ben-Hur Albergaria, Brenda Nazaré Gomes Silva, Álvaro N Atallah, Virginia Fernandes Moça Trevisani, Ben-Hur Albergaria. 2010. Intravenous zoledronate for postmenopausal osteoporosis. .
CrossRef60
Weng-Foung Huang, Yi-Wen Tsai, Yu-Wen Wen, Fei-Yuan Hsiao, Ken N. Kuo, Chia-Rung Tsai. (2010) Osteoporosis treatment and atrial fibrillation. Menopause 17:1, 57-63
CrossRef61
J. Chris Gallagher, Adarsh J. Sai. (2010) Bisphosphonate use in osteoporosis. Menopause 17:1, 5-7
CrossRef62
M. A. Lawson, Z. Xia, B. L. Barnett, J. T. Triffitt, R. J. Phipps, J. E. Dunford, R. M. Locklin, F. H. Ebetino, R. G. G. Russell. (2010) Differences between bisphosphonates in binding affinities for hydroxyapatite. Journal of Biomedical Materials Research Part B: Applied Biomaterials 92B:1, 149-155
CrossRef63
Kendall F. Moseley, Suzanne M. Jan de Beur. 2010. Osteoporosis in Men and Women. , 716-736.
CrossRef64
Glen M. Blake, Amelia E.B. Moore, Ignac Fogelman. (2009) Quantitative Studies of Bone Using 99mTc-Methylene Diphosphonate Skeletal Plasma Clearance. Seminars in Nuclear Medicine 39:6, 369-379
CrossRef65
Michael McClung, Paul Miller, Chris Recknor, Peter Mesenbrink, Christina Bucci-Rechtweg, Claude-Laurent Benhamou. (2009) Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass. Obstetrics & Gynecology 114:5, 999-1007
CrossRef66
Chong Wee Foo, Eric Yukumoto, Richard DeJournett, Douglas W. Johnson. (2009) Iatrogenic osteoporosis in dermatology. International Journal of Dermatology 48:10, 1035-1043
CrossRef67
Stephanie L. Hines, Betty Mincey, Todor Dentchev, Jeff A. Sloan, Edith A. Perez, David B. Johnson, Paul L. Schaefer, Steve Alberts, Heshan Liu, Stephen Kahanic, Miroslaw A. Mazurczak, Daniel A. Nikcevich, Charles L. Loprinzi. (2009) Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Research and Treatment 117:3, 603-609
CrossRef68
S. Greiner, A. Kadow-Romacker, G. Schmidmaier, B. Wildemann. (2009) Cocultures of osteoblasts and osteoclasts are influenced by local application of zoledronic acid incorporated in a poly(D,L-lactide) implant coating. Journal of Biomedical Materials Research Part A 91A:1, 288-295
CrossRef69
E. Michael Lewiecki. (2009) Current and Emerging Pharmacologic Therapies for the Management of Postmenopausal Osteoporosis. Journal of Women's Health 18:10, 1615-1626
CrossRef70
Sheila A Doggrell. (2009) Clinical efficacy and safety of zoledronic acid in osteoporosis and Paget’s bone disease. Expert Review of Endocrinology & Metabolism 4:5, 405-415
CrossRef71
Peng Songlin, Zhang Ge, He Yixin, Wang Xinluan, Leung Pingchung, Leung Kwoksui, Qin Ling. (2009) Epimedium-derived flavonoids promote osteoblastogenesis and suppress adipogenesis in bone marrow stromal cells while exerting an anabolic effect on osteoporotic bone. Bone 45:3, 534-544
CrossRef72
Julie A Switzer, Susan Jaglal, Earl R Bogoch. (2009) Overcoming Barriers to Osteoporosis Care in Vulnerable Elderly Patients With Hip Fractures. Journal of Orthopaedic Trauma 23:6, 454-459
CrossRef73
Ian Chapman, Hugh Greville, Peter R. Ebeling, Susannah J. King, Tom Kotsimbos, Patricia Nugent, Rosie Player, Duncan J. Topliss, Janet Warner, John W. Wilson. (2009) Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF). Clinical Endocrinology 70:6, 838-846
CrossRef74
Donald Basel, Robert D. Steiner. (2009) Osteogenesis imperfecta: Recent findings shed new light on this once well-understood condition. Genetics in Medicine 11:6, 375-385
CrossRef75
Bruno Frediani, Luca Cavalieri, Giovanni Cremonesi. (2009) Clodronic Acid Formulations Available in Europe and their Use in Osteoporosis. Clinical Drug Investigation 29:6, 359-379
CrossRef76
Regina Ebert, Sabine Zeck, Ralf Krug, Jutta Meissner-Weigl, Doris Schneider, Lothar Seefried, Jochen Eulert, Franz Jakob. (2009) Pulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiation. Bone 44:5, 858-864
CrossRef77
, Hans Peter Dimai, Peter Pietschmann, Heinrich Resch, Elisabeth Preisinger, Astrid Fahrleitner-Pammer, Harald Dobnig, Klaus Klaushofer. (2009) Österreichischer Leitfaden zur medikamentösen Therapie der postmenopausalen Osteoporose – Update 2009. Wiener Medizinische Wochenschrift 159:S122, 1-34
CrossRef78
E. Michael Lewiecki, Sanford Baim, John P. Bilezikian, Richard Eastell, Meryl S. LeBoff, Paul D. Miller. (2009) 2008 Santa Fe Bone Symposium: Update on Osteoporosis. Journal of Clinical Densitometry 12:2, 135-157
CrossRef79
S. Casari, L. Sinigaglia. (2009) L’aderenza alle terapie per l’osteoporosi: l’esempio dei bisfosfonati. Archivio di Ortopedia e Reumatologia 119:3-4, 28-30
CrossRef80
S. Seitz, M. Schieker, W. Mutschler. (2009) Zoledronsäure 1-mal jährlich zur Behandlung der postmenopausalen Osteoporose. Der Unfallchirurg 112:3, 346-348
CrossRef81
T. Jared Bunch, Jeffrey L. Anderson, Heidi T. May, Joseph B. Muhlestein, Benjamin D. Horne, Brian G. Crandall, J. Peter Weiss, Donald L. Lappé, Jeffrey S. Osborn, John D. Day. (2009) Relation of Bisphosphonate Therapies and Risk of Developing Atrial Fibrillation. The American Journal of Cardiology 103:6, 824-828
CrossRef82
Ego Seeman. (2009) To stop or not to stop, that is the question. Osteoporosis International 20:2, 187-195
CrossRef83
Peyman Hadji. (2009) Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Critical Reviews in Oncology/Hematology 69:1, 73-82
CrossRef84
Jeannie Huang, Linda Meixner, Susan Fernandez, J Allen McCutchan. (2009) A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS 23:1, 51-57
CrossRef85
Ian R. Reid. (2009) Osteonecrosis of the jaw — Who gets it, and why?. Bone 44:1, 4-10
CrossRef86
Brian L. Foster, Kevin A. Tompkins, R. Bruce Rutherford, Hai Zhang, Emily Y. Chu, Hanson Fong, Martha J. Somerman. (2008) Phosphate: Known and potential roles during development and regeneration of teeth and supporting structures. Birth Defects Research Part C: Embryo Today: Reviews 84:4, 281-314
CrossRef87
P. Szulc, P. D. Delmas. (2008) Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporosis International 19:12, 1683-1704
CrossRef88
Pavan BHARGAVA, Debashish DANDA. (2008) Osteoporosis in ankylosing spondylitis. International Journal of Rheumatic Diseases 11:4, 374-380
CrossRef89
Mark A Perazella, Glen S Markowitz. (2008) Bisphosphonate nephrotoxicity. Kidney International 74:11, 1385-1393
CrossRef90
Carrie A Phillipi, Tracey Remmington, Robert D Steiner, Carrie A Phillipi. 2008. Bisphosphonate therapy for osteogenesis imperfecta. .
CrossRef91
Paul D. Miller. (2008) Anti-resorptives in the management of osteoporosis. Best Practice & Research Clinical Endocrinology & Metabolism 22:5, 849-868
CrossRef92
F. P. Coxon. (2008) An Update on the Pharmacology of Bisphosphonates and Analogues with Lower Bone Affinity. IBMS BoneKEy 5:10, 357-369
CrossRef93
Marie-Hélène Lafage-Proust. (2008) Once-yearly intravenous zoledronate does not impair renal function in postmenopausal women. Kidney International 74:5, 557-559
CrossRef94
Steven Boonen, Deborah E Sellmeyer, Kurt Lippuner, Alexander Orlov-Morozov, Ken Abrams, Peter Mesenbrink, Erik F Eriksen, Paul D Miller. (2008) Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney International 74:5, 641-648
CrossRef95
M. T. Drake, B. L. Clarke, S. Khosla. (2008) Bisphosphonates: Mechanism of Action and Role in Clinical Practice. Mayo Clinic Proceedings 83:9, 1032-1045
CrossRef96
Mark J Bolland, Andrew B Grey, Anne M Horne, Simon E Briggs, Mark G Thomas, Rod B Ellis-Pegler, Karen E Callon, Greg D Gamble, Ian R Reid. (2008) Effects of Intravenous Zoledronate on Bone Turnover and BMD Persist for at Least 24 Months. Journal of Bone and Mineral Research 23:8, 1304-1308
CrossRef97
PATRICIA O'MALLEY. (2008) A Once-a-Year Intravenous Treatment of Osteoporosis in Postmenopausal Women. Clinical Nurse Specialist 22:4, 169-171
CrossRef98
&NA;. (2008) Adverse-effect profiles of bisphosphonates are largely determined by their route of administration. Drugs & Therapy Perspectives 24:7, 23-26
CrossRef99
Nanda K. Thudi, Chelsea K. Martin, Murali V.P. Nadella, Soledad A. Fernandez, Jillian L. Werbeck, Joseph J. Pinzone, Thomas J. Rosol. (2008) Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions. The Prostate 68:10, 1116-1125
CrossRef100
R. G. G. Russell, N. B. Watts, F. H. Ebetino, M. J. Rogers. (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporosis International 19:6, 733-759
CrossRef101
J. González Macías, N. Guañabens Gay, C. Gómez Alonso, L. del Río Barquero, M. Muñoz Torres, M. Delgado, L. Pérez Edo, J. Bernardino Díaz López, E. Jódar Gimeno, F. Hawkins Carranza. (2008) Guías de práctica clínica en la osteoporosis posmenopáusica, glucocorticoidea y del varón. Sociedad Española de Investigación Ósea y del Metabolismo Mineral. Revista Clínica Española 208, 1-24
CrossRef102
Allen E. Goodship, Gordon W. Blunn, Jonathan Green, Melanie J. Coathup. (2008) Prevention of strain-related osteopenia in aseptic loosening of hip prostheses using perioperative bisphosphonate. Journal of Orthopaedic Research 26:5, 693-703
CrossRef103
Roland D Chapurlat. (2008) Single annual injectable treatment for postmenopausal osteoporosis. Expert Opinion on Drug Delivery 5:5, 583-591
CrossRef104
Pierre D. Delmas. (2008) Clinical Potential of RANKL Inhibition for the Management of Postmenopausal Osteoporosis and Other Metabolic Bone Diseases. Journal of Clinical Densitometry 11:2, 325-338
CrossRef105
Adam M Brufsky. (2008) Zoledronic acid for cancer therapy-induced and postmenopausal bone loss. Expert Opinion on Pharmacotherapy 9:6, 1013-1028
CrossRef106
, J. A. Kanis, N. Burlet, C. Cooper, P. D. Delmas, J.-Y. Reginster, F. Borgstrom, R. Rizzoli. (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International 19:4, 399-428
CrossRef107
Amy Warriner, Kenneth G. Saag. (2008) Clinical trials report. Current Rheumatology Reports 10:2, 89-91
CrossRef108
N. B. Watts, A. Chines, W. P. Olszynski, C. D. McKeever, M. R. McClung, X. Zhou, A. Grauer. (2008) Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporosis International 19:3, 365-372
CrossRef109
Hazim Sadideen, Adrian Covic, David Goldsmith. (2008) Mineral and bone disorder after renal transplantation: a review. International Urology and Nephrology 40:1, 171-184
CrossRef110
Sheila A Doggrell. (2008) New horizons for zoledronic acid: results of the HORIZON trials in postmenopausal women with osteoporosis and after hip fracture. Expert Opinion on Pharmacotherapy 9:4, 663-668
CrossRef111
I. Byrjalsen, D. J. Leeming, P. Qvist, C. Christiansen, M. A. Karsdal. (2008) Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. Osteoporosis International 19:3, 339-348
CrossRef112
J. E. M. Brouwers, F. M. Lambers, J. A. Gasser, B. Rietbergen, R. Huiskes. (2008) Bone Degeneration and Recovery after Early and Late Bisphosphonate Treatment of Ovariectomized Wistar Rats Assessed by In Vivo Micro-Computed Tomography. Calcified Tissue International 82:3, 202-211
CrossRef113
William C. Shakespeare, Yihan Wang, Regine Bohacek, Terry Keenan, Raji Sundaramoorthi, Chet Metcalf, Anne Dilauro, Sonya Roeloffzen, Shuangying Liu, Jennifer Saltmarsh, Guru Paramanathan, David Dalgarno, Surinder Narula, Selvi Pradeepan, Marie Rose van Schravendijk, Jeff Keats, Mary Ram, Shuenn Liou, Susan Adams, Scott Wardwell, Julie Bogus, John Iuliucci, Manfred Weigele, Lianping Xing, Brendan Boyce, Tomi K. Sawyer. (2008) SAR of Carbon-Linked, 2-Substituted Purines: Synthesis and Characterization of AP23451 as a novel Bone-Targeted Inhibitor of Src Tyrosine Kinase With In Vivo Anti-Resorptive Activity. Chemical Biology & Drug Design 71:2, 97-105
CrossRef114
I. R. Reid. (2008) Pathogenesis of Osteonecrosis of the Jaw. IBMS BoneKEy 5:2, 69-77
CrossRef115
B.L. Clarke. (2008) Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. Yearbook of Endocrinology 2008, 212-214
CrossRef116
Peter R Ebeling, David B Burr. (2008) Editorial: Positive Effects of Intravenous Zoledronic Acid on Bone Remodeling and Structure: Are Different Effects on Osteoblast Activity to Other Oral Bisphosphonates Responsible?. Journal of Bone and Mineral Research 23:1, 2-5
CrossRef117
Sohita Dhillon, Katherine A Lyseng-Williamson. (2008) Zoledronic Acid. Drugs 68:4, 507-534
CrossRef118
Robert R Recker, Pierre D Delmas, Johan Halse, Ian R Reid, Steven Boonen, Pedro A García-Hernandez, Jerzy Supronik, E Michael Lewiecki, Luis Ochoa, Paul Miller, Huilin Hu, Peter Mesenbrink, Florian Hartl, Juerg Gasser, Erik F Eriksen. (2008) Effects of Intravenous Zoledronic Acid Once Yearly on Bone Remodeling and Bone Structure. Journal of Bone and Mineral Research 23:1, 6-16
CrossRef119
Stefan Greiner, Anke Kadow-Romacker, Britt Wildemann, Philipp Schwabe, Gerhard Schmidmaier. (2007) Bisphosphonates incorporated in a poly(D,L-lactide) implant coating inhibit osteoclast like cellsin vitro. Journal of Biomedical Materials Research Part A 83A:4, 1184-1191
CrossRef120
N. M. H. McLeod, B. J. B. Davies, P. A. Brennan. (2007) Bisphosphonate osteonecrosis of the jaws; an increasing problem for the dental practitioner. BDJ 203:11, 641-644
CrossRef121
Francesco Bertoldo, Daniele Santini, Vincenzo Lo Cascio. (2007) Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle. Nature Clinical Practice Oncology 4:12, 711-721
CrossRef122
J. Borrás-Blasco, D. Rosique-Robles, V. Giner-Marco, A. Galan-Brotons, E. Casterá, S. Costa. (2007) Possible delayed onset of osteonecrosis of the jaw in association with zoledronic acid. Journal of Clinical Pharmacy and Therapeutics 32:6, 651-654
CrossRef123
E Michael Lewiecki, Paul D Miller. (2007) Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opinion on Drug Safety 6:6, 663-672
CrossRef124
E. Michael Lewiecki. (2007) Long dosing intervals in the treatment of postmenopausal osteoporosis. Current Medical Research and Opinion 23:11, 2617-2625
CrossRef125
R. Bartl, C.J. Thaler. (2007) Leitliniengerechte Diagnostik und Therapie der postmenopausalen Osteoporose. Der Gynäkologe 40:11, 913-923
CrossRef126
Jun Iwamoto, Tsuyoshi Takeda, Yoshihiro Sato. (2007) Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis – usefulness of alendronate and risedronate. Expert Opinion on Pharmacotherapy 8:16, 2743-2756
CrossRef127
Jean-Yves Reginster, Nansa Burlet, Pierre Close, Olivier Bruyere. (2007) Injectable bisphosphonates for the treatment of osteoporosis. Women's Health 3:6, 719-723
CrossRef128
Lyles, Kenneth W., Colón-Emeric, Cathleen S., Magaziner, Jay S., Adachi, Jonathan D., Pieper, Carl F., Mautalen, Carlos, Hyldstrup, Lars, Recknor, Chris, Nordsletten, Lars, Moore, Kathy A., Lavecchia, Catherine, Zhang, Jie, Mesenbrink, Peter, Hodgson, Patricia K., Abrams, Ken, Orloff, John J., Horowitz, Zebulun, Eriksen, Erik Fink, Boonen, Steven, . (2007) Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. New England Journal of Medicine 357:18, 1799-1809
Full Text129
Jennifer Grossman, Catherine H. MacLean. (2007) Quality Indicators for the Care of Osteoporosis in Vulnerable Elders. Journal of the American Geriatrics Society 55, S392-S402
CrossRef130
Roland D Chapurlat, Monique Arlot, Brigitte Burt-Pichat, Pascale Chavassieux, Jean Paul Roux, Nathalie Portero-Muzy, Pierre D Delmas. (2007) Microcrack Frequency and Bone Remodeling in Postmenopausal Osteoporotic Women on Long-Term Bisphosphonates: A Bone Biopsy Study. Journal of Bone and Mineral Research 22:10, 1502-1509
CrossRef131
Takahiro Hashimoto, Mitsunori Shigetomi, Teruyasu Ohno, Tsunemitsu Matsunaga, Keiichi Muramatsu, Hiroshi Tanaka, Toshihiro Sugiyama, Toshihiko Taguchi. (2007) Sequential Treatment with Intermittent Low-Dose Human Parathyroid Hormone (1-34) and Bisphosphonate Enhances Large-Size Skeletal Reconstruction by Vascularized Bone Transplantation. Calcified Tissue International 81:3, 232-239
CrossRef132
Hosam K. Kamel. (2007) Update on Osteoporosis Management in Long-term Care: Focus on Bisphosphonates. Journal of the American Medical Directors Association 8:7, 434-440
CrossRef133
Ian R. Reid, Mark J. Bolland, Andrew B. Grey. (2007) Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?. Bone 41:3, 318-320
CrossRef134
Ann Cranney, Jonathan D. Adachi. (2007) Bisphosphonates for the Treatment of Postmenopausal Osteoporosis: An Update. Clinical Reviews in Bone and Mineral Metabolism 5:3, 145-152
CrossRef135
Andrew Grey. (2007) Emerging pharmacologic therapies for osteoporosis. Expert Opinion on Emerging Drugs 12:3, 493-508
CrossRef136
J. P. Devogelaer, J. P. Brown, P. Burckhardt, P. J. Meunier, S. Goemaere, K. Lippuner, J. J. Body, G. Samsioe, D. Felsenberg, T. Fashola, L. Sanna, C. E. Ortmann, U. Trechsel, J. Krasnow, E. F. Eriksen, P. Garnero. (2007) Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporosis International 18:9, 1211-1218
CrossRef137
(2007) Yearly Zoledronic Acid in Postmenopausal Osteoporosis. New England Journal of Medicine 357:7, 711-715
Full Text138
Fabian von Knoch, Christina Eckhardt, Claude I. Alabre, Erich Schneider, Harry E. Rubash, Arun S. Shanbhag. (2007) Anabolic effects of bisphosphonates on peri-implant bone stock. Biomaterials 28:24, 3549-3559
CrossRef139
F. Finter, F.M. Mottaghy, R. Kuefer, R.E. Hautmann, L. Rinnab. (2007) Systemische Therapieansätze bei Knochenmetastasen urogenitaler Tumoren. Der Urologe 46:8, 904-912
CrossRef140
Stuart L. Silverman, Michael Maricic. (2007) Recent Developments in Bisphosphonate Therapy. Seminars in Arthritis and Rheumatism 37:1, 1-12
CrossRef141
Michael McClung, Robert Recker, Paul Miller, Darrell Fiske, Jerome Minkoff, Audrey Kriegman, Wenchun Zhou, Mathews Adera, Jenny Davis. (2007) Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 41:1, 122-128
CrossRef142
M. Bodingbauer, T. Wekerle, B. Pakrah, P. Roschger, M. Peck-Radosavljevic, G. Silberhumer, S. Grampp, S. Rockenschaub, G. Berlakovich, R. Steininger, K. Klaushofer, R. Oberbauer, F. Mühlbacher. (2007) Prophylactic Bisphosphonate Treatment Prevents Bone Fractures After Liver Transplantation. American Journal of Transplantation 7:7, 1763-1769
CrossRef143
Michael Maricic. (2007) New and emerging treatments for osteoporosis. Current Opinion in Rheumatology 19:4, 364-369
CrossRef144
Nicholas S Chew, Peter P Doran, William G Powderly. (2007) Osteopenia and osteoporosis in HIV: pathogenesis and treatment. Current Opinion in HIV and AIDS 2:4, 318-323
CrossRef145
Estee P. Wang, Leonard B. Kaban, Gordon J. Strewler, Noopur Raje, Maria J. Troulis. (2007) Incidence of Osteonecrosis of the Jaw in Patients With Multiple Myeloma and Breast or Prostate Cancer on Intravenous Bisphosphonate Therapy. Journal of Oral and Maxillofacial Surgery 65:7, 1328-1331
CrossRef146
David Hosking. (2007) Zoledronic acid in Paget’s disease. Therapy 4:4, 391-397
CrossRef147
J. Shapiro, B. Smith, T. Beck, P. Ballard, M. Dapthary, K. BrintzenhofeSzoc, J. Caminis. (2007) Treatment with Zoledronic Acid Ameliorates Negative Geometric Changes in the Proximal Femur following Acute Spinal Cord Injury. Calcified Tissue International 80:5, 316-322
CrossRef148
V. Z. C. Borba, G. Paz-Filho, C. A. M. Kulak, M. J. Seibel, J. P. Bilezikian. (2007) Bone turnover 18 months after a single intravenous dose of zoledronic acid. International Journal of Clinical Practice 61:6, 1058-1062
CrossRef149
G. Lümmen, H. Rübben, T. Schneider, H. Sperling. (2007) Prävention der Osteoporose – wichtig für den Urologen?. Der Urologe 46:6, 651-655
CrossRef150
John A. Sunyecz, Richard Derman. (2007) Update on the Use of Bisphosphonates in the Management of Postmenopausal Osteoporosis by Obstetricians-Gynecologists. Obstetrical & Gynecological Survey 62:6, 407-416
CrossRef151
Negin Amanat, Michelle McDonald, Craig Godfrey, Lynne Bilston, David Little. (2007) Optimal Timing of a Single Dose of Zoledronic Acid to Increase Strength in Rat Fracture Repair. Journal of Bone and Mineral Research 22:6, 867-876
CrossRef152
Compston, Juliet, . (2007) Treatments for Osteoporosis — Looking beyond the HORIZON. New England Journal of Medicine 356:18, 1878-1880
Full Text153
Black, Dennis M., Delmas, Pierre D., Eastell, Richard, Reid, Ian R., Boonen, Steven, Cauley, Jane A., Cosman, Felicia, Lakatos, Péter, Leung, Ping Chung, Man, Zulema, Mautalen, Carlos, Mesenbrink, Peter, Hu, Huilin, Caminis, John, Tong, Karen, Rosario-Jansen, Theresa, Krasnow, Joel, Hue, Trisha F., Sellmeyer, Deborah, Eriksen, Erik Fink, Cummings, Steven R., . (2007) Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. New England Journal of Medicine 356:18, 1809-1822
Full Text154
Kenneth Saag, Robert Lindsay, Audrey Kriegman, Emily Beamer, Wenchun Zhou. (2007) A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 40:5, 1238-1243
CrossRef155
Priya Grewal, Paul Martin. (2007) Pretransplant Management of the Cirrhotic Patient. Clinics in Liver Disease 11:2, 431-449
CrossRef156
Rick Bransford, Elisabeth Goergens, Julie Briody, Negin Amanat, Andrew Cree, David Little. (2007) Effect of zoledronic acid in an L6–L7 rabbit spine fusion model. European Spine Journal 16:4, 557-562
CrossRef157
Rachel Layman, Karin Olson, Catherine Van Poznak. (2007) Bisphosphonates for Breast Cancer: Questions Answered, Questions Remaining. Hematology/Oncology Clinics of North America 21:2, 341-367
CrossRef158
S. Greiner, A. Kadow-Romacker, M. Lübberstedt, G. Schmidmaier, B. Wildemann. (2007) The effect of zoledronic acid incorporated in a poly(D,L-lactide) implant coating on osteoblastsin vitro. Journal of Biomedical Materials Research Part A 80A:4, 769-775
CrossRef159
Margareta Verdrengh, Hans Carlsten, Claes Ohlsson, Andrej Tarkowski. (2007) Addition of bisphosphonate to antibiotic and anti-inflammatory treatment reduces bone resorption in experimentalStaphylococcus aureus-induced arthritis. Journal of Orthopaedic Research 25:3, 304-310
CrossRef160
Julian MR Mathoo, Lisa Becker, Dinesh Kumbhare, Jonathan D Adachi. (2007) Therapeutic advances in the treatment of osteoporosis. Expert Opinion on Therapeutic Patents 17:3, 277-285
CrossRef161
Roberto Civitelli, Nicola Napoli, Reina Armamento-Villareal. (2007) Use of intravenous bisphosphonates in osteoporosis. Current Osteoporosis Reports 5:1, 8-13
CrossRef162
Johann D. Ringe, Parvis Farahmand. (2007) Advances in the management of corticosteroid-induced osteoporosis with bisphosphonates. Clinical Rheumatology 26:4, 474-484
CrossRef163
Ugis Gruntmanis. (2007) Male Osteoporosis: Deadly, but Ignored. The American Journal of the Medical Sciences 333:2, 85-92
CrossRef164
Richard Keen. (2007) Osteoporosis: strategies for prevention and management. Best Practice & Research Clinical Rheumatology 21:1, 109-122
CrossRef165
Sumapa Chaiamnuay, Kenneth G. Saag. (2007) Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates?. Reviews in Endocrine and Metabolic Disorders 7:1-2, 101-112
CrossRef166
Pauline M Camacho, Reina Armamento-Villareal, Michael Kleerekoper. (2007) Postmenopausal osteoporosis: an update on current and future therapeutic options. Expert Review of Endocrinology & Metabolism 2:1, 79-90
CrossRef167
Francis H. Glorieux. (2007) Treatment of Osteogenesis Imperfecta: Who, Why, What?. Hormone Research 68:5, 8-11
CrossRef168
William Strampel, Ronald Emkey, Roberto Civitelli. (2007) Safety Considerations with Bisphosphonates for the Treatment of Osteoporosis. Drug Safety 30:9, 755-763
CrossRef169
Byung Joo Song, Seon Wook Cha, Ja Seong Bae, Young Jin Seo, Woo Chan Park, Han-Seong Kim, Se Jung Oh, Jeong Soo Kim, Sang Seol Jung. (2007) Role of Zoledronic Acid on Bone Loss by Letrozole. Journal of Breast Cancer 10:1, 43
CrossRef170
Jean-Yves Reginster, Olivier Malaise, Audrey Neuprez, Victor-Emmanuel Jouret, Pierre Close. (2007) Intermittent Bisphosphonate Therapy in Postmenopausal Osteoporosis. Drugs & Aging 24:5, 351-359
CrossRef171
Richard Eastell. (2007) Skeletal Health in Adulthood. Hormone Research 67:1, 23-27
CrossRef172
Eric Lespessailles. (2007) A forgotten challenge when treating osteoporosis: Getting patients to take their meds. Joint Bone Spine 74:1, 7-8
CrossRef173
Jean E Mulder, Nikheel S Kolatkar, Meryl S LeBoff. (2006) Drug Insight: existing and emerging therapies for osteoporosis. Nature Clinical Practice Endocrinology & Metabolism 2:12, 670-680
CrossRef174
Vassilios Perifanis, Timoleon Vyzantiadis, Konstantinos Tziomalos, Sofia Vakalopoulou, Vassilia Garipidou, Miranda Athanassiou-Metaxa, Faidon Harsoulis. (2006) Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia. Annals of Hematology 86:1, 23-30
CrossRef175
Natasha Jordan, Maurice Barry, Eithne Murphy. (2006) Comparative effects of antiresorptive agents on bone mineral density and bone turnover in postmenopausal women. Clinical Interventions in Aging 1:4, 377-387
CrossRef176
Katri P Palonen, Kenneth G Saag. (2006) Improving the quality of clinical care for patients with osteoporosis. Expert Review of Pharmacoeconomics & Outcomes Research 6:6, 641-645
CrossRef177
Ian R Reid. (2006) Zoledronate: Efficacy and Safety. Journal of Bone and Mineral Research 21:S2, P83-P87
CrossRef178
Ian R. Reid. (2006) Emerging Issues With Bisphosphonates. Rheumatic Disease Clinics of North America 32:4, 691-702
CrossRef179
Liana Fraenkel, Barbara Gulanski, Dick Wittink. (2006) Patient treatment preferences for osteoporosis. Arthritis & Rheumatism 55:5, 729-735
CrossRef180
D. J. Leeming, P. Alexandersen, M. A. Karsdal, P. Qvist, S. Schaller, L. B. Tankó. (2006) An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice. European Journal of Clinical Pharmacology 62:10, 781-792
CrossRef181
Michael Maricic. (2006) Zoledronic acid: future potential use in rheumatology. Future Rheumatology 1:5, 541-548
CrossRef182
Jürg A. Gasser, Jonathan R. Green, Victor Shen, Peter Ingold, Andrea Rebmann, Ajay S. Bhatnagar, Dean B. Evans. (2006) A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats. Bone 39:4, 787-795
CrossRef183
Laura B Hansen. (2006) Osteoporosis update: effective prevention and treatment. Expert Review of Pharmacoeconomics & Outcomes Research 6:5, 525-540
CrossRef184
Christopher J. DeWald, Thomas Stanley. (2006) Instrumentation-Related Complications of Multilevel Fusions for Adult Spinal Deformity Patients Over Age 65. Spine 31:Suppl, S144-S151
CrossRef185
Christopher W. Ryan, Dezheng Huo, Laurence M. Demers, Tomasz M. Beer, Leo V. Lacerna. (2006) Zoledronic Acid Initiated During the First Year of Androgen Deprivation Therapy Increases Bone Mineral Density in Patients With Prostate Cancer. The Journal of Urology 176:3, 972-978
CrossRef186
C. P. Gilfillan, B. J. S. Strauss, C. P. Rodda, D. K. Bowden, A.-M. Kean, M. Obaid, B. A. Crawford. (2006) A Randomized, Double-Blind, Placebo-Controlled Trial of Intravenous Zoledronic Acid in the Treatment of Thalassemia-Associated Osteopenia. Calcified Tissue International 79:3, 138-144
CrossRef187
Jong In Lee, Hye Won Kim, Won Ihl Rhee, Joo Hyun Park, Seong Hoon Lim, Sun Im, Young Jin Ko. (2006) The beneficial effect of intravenous zoledronic acid therapy following an acute stroke in rats. Bone 39:2, 377-382
CrossRef188
E Michael Lewiecki. (2006) Prevention of osteoporotic fractures. Aging Health 2:4, 649-659
CrossRef189
Pierre Close, Audrey Neuprez, Jean-Yves Reginster. (2006) Developments in the pharmacotherapeutic management of osteoporosis. Expert Opinion on Pharmacotherapy 7:12, 1603-1615
CrossRef190
K. Thompson. (2006) Bisphosphonates and T-Cells: New Insights into Old Drugs. International Bone and Mineral Society Knowledge Environment 3:8, 5-13
CrossRef191
Philip Sambrook, Cyrus Cooper. (2006) Osteoporosis. The Lancet 367:9527, 2010-2018
CrossRef192
Walter Jonat, Felix Hilpert. (2006) Optimizing the use of aromatase inhibitors in adjuvant therapy for postmenopausal patients with hormone-responsive early breast cancer: current and future prospects. Journal of Cancer Research and Clinical Oncology 132:6, 343-355
CrossRef193
Christian Eberhardt, Ulla Stumpf, Jochen Brankamp, Markus Schwarz, Andreas H Kurth. (2006) Osseointegration of Cementless Implants with Different Bisphosphonate Regimens. Clinical Orthopaedics and Related Research 447, 195-200
CrossRef194
Socrates E. Papapoulos. (2006) Bisphosphonate actions: Physical chemistry revisited. Bone 38:5, 613-616
CrossRef195
G.H. Nancollas, R. Tang, R.J. Phipps, Z. Henneman, S. Gulde, W. Wu, A. Mangood, R.G.G. Russell, F.H. Ebetino. (2006) Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone 38:5, 617-627
CrossRef196
Stephen J. Jarrett, Philip G. Conaghan, Victor S. Sloan, Philemon Papanastasiou, Christine-Elke Ortmann, Philip J. O'Connor, Andrew J. Grainger, Paul Emery. (2006) Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis & Rheumatism 54:5, 1410-1414
CrossRef197
Chih-Tai Leu, Eva Luegmayr, Leonard P. Freedman, Gideon A. Rodan, Alfred A. Reszka. (2006) Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. Bone 38:5, 628-636
CrossRef198
Adam Brufsky. (2006) Management of Cancer-Treatment–Induced Bone Loss in Postmenopausal Women Undergoing Adjuvant Breast Cancer Therapy: A Z-FAST Update. Seminars in Oncology 33, 13-17
CrossRef199
Charles A Morris, John A. Carrino, Philipp Lang, Daniel H. Solomon. (2006) Incidental Vertebral Fractures on Chest Radiographs. Recognition, Documentation, and Treatment. Journal of General Internal Medicine 21:4, 352-356
CrossRef200
Roland D Chapurlat, Pierre D Delmas. (2006) Drug Insight: bisphosphonates for postmenopausal osteoporosis. Nature Clinical Practice Endocrinology & Metabolism 2:4, 211-219
CrossRef201
Miriam Delaney. (2006) Understanding Bone Strength. The Endocrinologist 16:2, 79-85
CrossRef202
Ville-Valtteri Välimäki, Niko Moritz, Jessica J. Yrjans, Eero Vuorio, Hannu T. Aro. (2006) Effect of zoledronic acid on incorporation of a bioceramic bone graft substitute. Bone 38:3, 432-443
CrossRef203
Whyte, Michael P., . (2006) The Long and the Short of Bone Therapy. New England Journal of Medicine 354:8, 860-863
Full Text204
Michael J. Gardner, Demetris Demetrakopoulos, Michael K. Shindle, Matthew H. Griffith, Joseph M. Lane. (2006) Osteoporosis and Skeletal Fractures. HSS Journal 2:1, 62-69
CrossRef205
Solomon Epstein. (2006) Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clinical Therapeutics 28:2, 151-173
CrossRef206
Alfred K. Pfister, Christine A. Welch, Melissa D. Lester, Mary K. Emmett, Paul D. Saville, Shea A. Duerring. (2006) Cost-effectiveness Strategies to Treat Osteoporosis in Elderly Women. Southern Medical Journal 99:2, 123-131
CrossRef207
Magnus Tägil, Per Aspenberg, Jörgen Åstrand. (2006) Systemic zoledronate precoating of a bone graft reduces bone resorption during remodeling. Acta Orthopaedica 77:1, 23-26
CrossRef208
Johann Ringe. (2006) Zoledronic acid in the treatment of Paget’s disease and other benign bone disorders. Expert Review of Endocrinology & Metabolism 1:1, 15-24
CrossRef209
Jean-Yves Reginster, Eric Abadie, Pierre Delmas, René Rizzoli, Willard Dere, Philippe Auwera, Bernard Avouac, Maria-Luisa Brandi, Anastasia Daifotis, Adolfo Diez-Perez, Gonzalo Calvo, Olof Johnell, Jean-Marc Kaufman, Gottfried Kreutz, Andrea Laslop, Fritz Lekkerkerker, Bruce Mitlak, Per Nilsson, John Orloff, Mary Smillie, Andrew Taylor, Yannis Tsouderos, Dominique Ethgen, Bruno Flamion. (2006) Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men. Osteoporosis International 17:1, 1-7
CrossRef210
Serge Cremers, Patrick Garnero. (2006) Biochemical Markers of Bone Turnover in the Clinical Development of Drugs for Osteoporosis and Metastatic Bone Disease. Drugs 66:16, 2031-2058
CrossRef211
Evan Romas. (2005) Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates. Best Practice & Research Clinical Rheumatology 19:6, 1065-1079
CrossRef212
Maarit Kellinsalmi, Hannu Monkkonen, Jukka Monkkonen, Hannu-Ville Leskela, Vilhelmiina Parikka, Martti Hamalainen, Petri Lehenkari. (2005) In vitro Comparison of Clodronate, Pamidronate and Zoledronic Acid Effects on Rat Osteoclasts and Human Stem Cell-Derived Osteoblasts. Basic <html_ent glyph="@amp;" ascii="&"/> Clinical Pharmacology <html_ent glyph="@amp;" ascii="&"/> Toxicology 97:6, 382-391
CrossRef213
Fabian von Knoch, Claude Jaquiery, Marc Kowalsky, Stefan Schaeren, Claude Alabre, Ivan Martin, Harry E. Rubash, Arun S. Shanbhag. (2005) Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials 26:34, 6941-6949
CrossRef214
Pirow J Bekker, Donna L Holloway, Amy S Rasmussen, Robyn Murphy, Steven W Martin, Philip T Leese, Gregory B Holmes, Colin R Dunstan, Alex M DePaoli. (2005) A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women. Journal of Bone and Mineral Research 20:12, 2274-2282
CrossRef215
Jean-Pierre Devogelaer, Yves Boutsen, Daniel H Manicourt. (2005) Bisphosphonate therapy for the treatment of postmenopausal osteoporosis. Aging Health 1:3, 459-474
CrossRef216
Thomas Pfister, Elke Atzpodien, Bernd Bohrmann, Frieder Bauss. (2005) Acute Renal Effects of Intravenous Bisphosphonates in the Rat. Basic <html_ent glyph="@amp;" ascii="&"/> Clinical Pharmacology <html_ent glyph="@amp;" ascii="&"/> Toxicology 97:6, 374-381
CrossRef217
Piet Geusens, David Reid. (2005) Newer drug treatments: Their effects on fracture prevention. Best Practice & Research Clinical Rheumatology 19:6, 983-989
CrossRef218
Matthew R Smith. (2005) Therapy Insight: osteoporosis during hormone therapy for prostate cancer. Nature Clinical Practice Urology 2:12, 608-615
CrossRef219
L Tauchmanovà, G De Simone, T Musella, F Orio, P Ricci, C Nappi, G Lombardi, A Colao, B Rotoli, C Selleri. (2005) Effects of various antireabsorptive treatments on bone mineral density in hypogonadal young women after allogeneic stem cell transplantation. Bone Marrow Transplantation
CrossRef220
Ronald C. Hamdy, Charles H. Chesnut, Margery L. Gass, Michael F. Holick, Edward S. Leib, Michael E. Lewiecki, Michael Maricic, Nelson B. Watts. (2005) Review of Treatment Modalities for Postmenopausal Osteoporosis. Southern Medical Journal 98:10, 1000-1014
CrossRef221
S. Schaller, K. Henriksen, P. Hoegh-Andersen, B.C. Søndergaard, E.U. Sumer, L.B. Tanko, P. Qvist, M.A. Karsdal. (2005) In Vitro, Ex Vivo , and In Vivo Methodological Approaches for Studying Therapeutic Targets of Osteoporosis and Degenerative Joint Diseases: How Biomarkers Can Assist?. ASSAY and Drug Development Technologies 3:5, 553-580
CrossRef222
Jean-Yves Reginster. (2005) Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis. Expert Opinion on Pharmacotherapy 6:13, 2301-2313
CrossRef223
Reid, Ian R., Miller, Paul, Lyles, Kenneth, Fraser, William, Brown, Jacques P., Saidi, Youssef, Mesenbrink, Peter, Su, Guoqin, Pak, Judy, Zelenakas, Ken, Luchi, Monica, Richardson, Peter, Hosking, David, . (2005) Comparison of a Single Infusion of Zoledronic Acid with Risedronate for Paget's Disease. New England Journal of Medicine 353:9, 898-908
Full Text224
Rosen, Clifford J., . (2005) Postmenopausal Osteoporosis. New England Journal of Medicine 353:6, 595-603
Full Text225
J Lester, R Coleman. (2005) Bone loss and the aromatase inhibitors. British Journal of Cancer 93, S16-S22
CrossRef226
Catherine Van Poznak, Nicholas P. Sauter. (2005) Clinical management of osteoporosis in women with a history of breast carcinoma. Cancer 104:3, 443-456
CrossRef227
Shabnam Foroughi, Calman Prussin. (2005) Clinical management of eosinophilic gastrointestinal disorders. Current Allergy and Asthma Reports 5:4, 259-261
CrossRef228
R. R. Recker, R. Gallagher, P. E. MacCosbe. (2005) Effect of Dosing Frequency on Bisphosphonate Medication Adherence in a Large Longitudinal Cohort of Women. Mayo Clinic Proceedings 80:7, 856-861
CrossRef229
Christian Wedemeyer, Fabian von Knoch, Andreas Pingsmann, Gero Hilken, Christoph Sprecher, Guido Saxler, Frank Henschke, Franz Löer, Marius von Knoch. (2005) Stimulation of bone formation by zoledronic acid in particle-induced osteolysis. Biomaterials 26:17, 3719-3725
CrossRef230
F von Knoch, C Wedemeyer, A Heckelei, C.h Sprecher, G Saxler, G Hilken, F Henschke, H Bereiter, F Löer, M von Knoch. (2005) Ein Vergleich der antiresorptiven Effekte von Bisphosphonaten und Statinen auf Polyethylenpartikel-induzierte Osteolysen / A Comparison of the Antiresorptive Effects of Bisphosphonates and Statins on Polyethylene Particle-Induced Osteolysis. Biomedizinische Technik/Biomedical Engineering 50:6, 195-200
CrossRef231
Guido R. Zanni, Jeannette Y. Wick. (2005) From Chronobiology to Chronotherapeutics. The Consultant Pharmacist 20:6, 480-491
CrossRef232
Allan Lipton. (2005) New therapeutic agents for the treatment of bone diseases. Expert Opinion on Biological Therapy 5:6, 817-832
CrossRef233
Anne D Letocha, Holly L Cintas, James F Troendle, James C Reynolds, Christopher E Cann, Edith J Chernoff, Suvimol C Hill, Lynn H Gerber, Joan C Marini. (2005) Controlled Trial of Pamidronate in Children With Types III and IV Osteogenesis Imperfecta Confirms Vertebral Gains but Not Short-Term Functional Improvement. Journal of Bone and Mineral Research 20:6, 977-986
CrossRef234
Marius von Knoch, Christian Wedemeyer, Andreas Pingsmann, Fabian von Knoch, Gero Hilken, Christoph Sprecher, Frank Henschke, Bertram Barden, Franz Löer. (2005) The decrease of particle-induced osteolysis after a single dose of bisphosphonate. Biomaterials 26:14, 1803-1808
CrossRef235
Jonathan R. Green. (2005) Zoledronic acid: pharmacologic profile of a potent bisphosphonate. Journal of Organometallic Chemistry 690:10, 2439-2448
CrossRef236
Chin Lee, Rosalind Ramsey-Goldman. (2005) Osteoporosis in Systemic Lupus Erythematosus Mechanisms. Rheumatic Disease Clinics of North America 31:2, 363-385
CrossRef237
David Greenblatt. (2005) Treatment of Postmenopausal Osteoporosis. Pharmacotherapy 25:4, 574-584
CrossRef238
Michael Maricic. (2005) Glucocorticoid-induced osteoporosis: Treatment options and guidelines. Current Osteoporosis Reports 3:1, 25-29
CrossRef239
Gregory W Stewart, Michael E Brunet, Melvin R Manning, Frederick A Davis. (2005) Treatment of Stress Fractures in Athletes With Intravenous Pamidronate. Clinical Journal of Sport Medicine 15:2, 92-94
CrossRef240
Andrew Grey, Ian R Reid. (2005) Emerging and potential therapies for osteoporosis. Expert Opinion on Investigational Drugs 14:3, 265-278
CrossRef241
José Luis Hernández Hernández, José Antonio Riancho Moral, Jesús González Macías. (2005) Bisfosfonatos intravenosos. Medicina Clínica 124:9, 348-354
CrossRef242
Redonda G. Miller, Katherine C. Chretien, Lucy A. Meoni, Ya-Pei Liu, Michael J. Klag, Michael A. Levine. (2005) Comparison of Intravenous Pamidronate to Standard Therapy for Osteoporosis. JCR: Journal of Clinical Rheumatology 11:1, 2-7
CrossRef243
Douglas P Kiel. (2005) Osteoporosis therapy in the elderly. Current Opinion in Internal Medicine 4:1, 46-51
CrossRef244
Roland D Chapurlat. (2005) Clinical Pharmacology of Potent New Bisphosphonates for Postmenopausal Osteoporosis. Treatments in Endocrinology 4:2, 115-125
CrossRef245
Kenneth C Lasseter, Arturo G Porras, Andrew Denker, Anu Santhanagopal, Anastasia Daifotis. (2005) Pharmacokinetic Considerations in Determining the Terminal Elimination Half-Lives of Bisphosphonates. Clinical Drug Investigation 25:2, 107-114
CrossRef246
Serge C L M Cremers, Goonaseelan (Colin) Pillai, Socrates E Papapoulos. (2005) Pharmacokinetics/Pharmacodynamics of Bisphosphonates. Clinical Pharmacokinetics 44:6, 551-570
CrossRef247
Peter Vestergaard. (2005) Antiresorptive Therapy for the Prevention of Postmenopausal Osteoporosis. Treatments in Endocrinology 4:5, 263-277
CrossRef248
Paula J Rackoff, Anthony Sebba. (2005) Optimizing Administration of Bisphosphonates in Women with Postmenopausal Osteoporosis. Treatments in Endocrinology 4:4, 245-251
CrossRef249
Jiliang Li, Masahiko Sato, Chris Jerome, Charles H. Turner, Zaifeng Fan, David B. Burr. (2005) Microdamage accumulation in the monkey vertebra does not occur when bone turnover is suppressed by 50% or less with estrogen or raloxifene. Journal of Bone and Mineral Metabolism 23:S1, 48-54
CrossRef250
Salvatore Alesci, Massimo U. De Martino, Ioannis Ilias, Philip W. Gold, George P. Chrousos. (2005) Glucocorticoid-Induced Osteoporosis: From Basic Mechanisms to Clinical Aspects. Neuroimmunomodulation 12:1, 1-19
CrossRef251
Richard Eastell. (2005) Management of Bone Health in Postmenopausal Women. Hormone Research 64:2, 76-80
CrossRef252
Terrence H Diamond. (2005) Pharmacotherapy of osteoporosis in men. Expert Opinion on Pharmacotherapy 6:1, 45-58
CrossRef253
Anders Ullén, Lena Lennartsson, Ulrika Harmenberg, Marie Hjelm-Eriksson, Karl Mikael Kälkner, Bo Lennernäs, Sten Nilsson. (2005) Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncologica 44:6, 644-650
CrossRef254
Agostino Gaudio, Nancy Morabito. (2005) Pharmacological Management of Severe Postmenopausal Osteoporosis. Drugs & Aging 22:5, 405-417
CrossRef255
Jana Ilic, Branka Kovacev, Ljiljana Babic, Nikola Curic, Jovanka Radosavljevic. (2005) Effects of alendronate on the markers of bone metabolic activity in postmenopausal women with osteoporosis. Medicinski pregled 58:7-8, 393-399
CrossRef256
Marie-Paul Lecart, Olivier Bruyere, Jean-Yves Reginster. (2004) Combination/sequential therapy in osteoporosis. Current Osteoporosis Reports 2:4, 123-130
CrossRef257
Matti S. Aapro. (2004) Long-term implications of bone loss in breast cancer. The Breast 13:1, 29-37
CrossRef258
R. Chapurlat, P.D. Delmas. (2004) Nouveaux traitements de l'ostéoporose. La Revue de Médecine Interne 25, S573-S579
CrossRef259
S.D. Reed, J.I. Radeva, G.A. Glendenning, F. Saad, K.A. Schulman. (2004) RE: COST-EFFECTIVENESS OF ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL COMPLICATIONS IN PATIENTS WITH PROSTATE CANCER. The Journal of Urology 172:5, 2082
CrossRef260
Theresa A. Guise, James A. Eastham. (2004) Cancer Treatment-Induced Bone Loss (CTIBL) in Prostate Cancer: Pathophysiology, Preclinical Findings, and Treatment with Zoledronic Acid. European Urology Supplements 3:5, 46-54
CrossRef261
(2004) RE: COST-EFFECTIVENESS OF ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL COMPLICATIONS IN PATIENTS WITH PROSTATE CANCER. The Journal of Urology 172:5, 2082
CrossRef262
Paul D Miller. (2004) Combination therapy for osteoporosis: parathyroid hormone and bisphosphonates. Current Opinion in Orthopaedics 15:5, 389-395
CrossRef263
Susan V Bukata, John H Healey. (2004) Bisphosphonates: a practical guide. Current Opinion in Orthopaedics 15:5, 376-377
CrossRef264
Harold A. Harvey. (2004) Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy. Seminars in Oncology 31, 23-30
CrossRef265
M YU, S BUYS. (2004) Medical management of skeletal metastasis. Neurosurgery Clinics of North America 15:4, 529-536
CrossRef266
Bruce E. Hillner. (2004) Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer 101:6, 1311-1322
CrossRef267
Peter Selby. (2004) Postmenopausal osteoporosis. Current Osteoporosis Reports 2:3, 101-106
CrossRef268
Tamara J. Vokes. (2004) Fibrous Dysplasia. The Endocrinologist 14:5, 245-249
CrossRef269
Dawn Hershman, Rashmi Narayanan. (2004) Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer. Current Oncology Reports 6:4, 277-284
CrossRef270
Gideon Rodan, Alfred Reszka, Ellis Golub, René Rizzoli. (2004) Bone safety of long-term bisphosphonate treatment. Current Medical Research and Opinion 20:8, 1291-1300
CrossRef271
Julie T Lin, Joseph M Lane. (2004) Osteoporosis. Clinical Orthopaedics and Related Research 425, 126-134
CrossRef272
Pirow J Bekker, Donna L Holloway, Amy S Rasmussen, Robyn Murphy, Steven W Martin, Philip T Leese, Gregory B Holmes, Colin R Dunstan, Alex M DePaoli. (2004) A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women. Journal of Bone and Mineral Research 19:7, 1059-1066
CrossRef273
Natalie A. Sims, Jonathan R. Green, Markus Glatt, Stephen Schlict, T. John Martin, Matthew T. Gillespie, Evan Romas. (2004) Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis & Rheumatism 50:7, 2338-2346
CrossRef274
Petra Herrak, Birgit G
rtz, Silvia Hayer, Kurt Redlich, Erika Reiter, J
CrossRef275
Nancy Price, Joyce A. O'Shaughnessy, Vinay K. Jain. (2004) The Prevention of Adjuvant Hormonal Therapy—Induced Bone Loss in Women with Breast Cancer. Clinical Breast Cancer 5:2, 97-99
CrossRef276
J.-Y. Reginster. (2004) Prevention of postmenopausal osteoporosis with pharmacological therapy: practice and possibilities. Journal of Internal Medicine 255:6, 615-628
CrossRef277
Jean-Claude Dumon, Fabrice Journé, Naı̈ma Kheddoumi, Laurence Lagneaux, Jean-Jacques Body. (2004) Cytostatic and Apoptotic Effects of Bisphosphonates on Prostate Cancer Cells. European Urology 45:4, 521-529
CrossRef278
S. S. Y. Chan, L. M. Nery, A. McElduff, E. G. Wilmshurst, G. R. Fulcher, B. G. Robinson, J. N. StIel, J. E. Gunton, P. B. Clifton-Bligh. (2004) Intravenous pamidronate in the treatment and prevention of osteoporosis. Internal Medicine Journal 34:4, 162-166
CrossRef279
Betty A. Mincey, Winston W. Tan. (2004) The Management of Bone Loss in Patients with Breast or Prostate Cancer. Supportive Cancer Therapy 1:3, 150-156
CrossRef280
Vasilios Perifanis, Timos Vyzantiadis, Sofia Vakalopoulou, Konstantinos Tziomalos, Vasilia Garypidou, Miranta Athanassiou-Metaxa, Fedon Harsoulis. (2004) Treatment of beta-thalassaemia-associated osteoporosis with zoledronic acid. British Journal of Haematology 125:1, 91-92
CrossRef281
Paul J Kostenuik, Brad Bolon, Sean Morony, Mark Daris, Zhaopo Geng, Christopher Carter, Jackie Sheng. (2004) Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice. Bone 34:4, 656-664
CrossRef282
Henry G. Bone, Werner Schurr. (2004) Intravenous bisphosphonate therapy for osteoporosis: Where do we stand?. Current Osteoporosis Reports 2:1, 24-30
CrossRef283
Carolyn Jachna, Abu T. Patel. (2004) Osteoporosis and perioperative medical management of hip fracture. Current Opinion in Orthopaedics 15:1, 2-7
CrossRef284
Keith Thompson, Michael J Rogers. (2004) Statins Prevent Bisphosphonate-Induced γ,δ-T-Cell Proliferation and Activation In Vitro. Journal of Bone and Mineral Research 19:2, 278-288
CrossRef285
Stanley B. Cohen. (2004) An update on bisphosphonates. Current Rheumatology Reports 6:1, 59-65
CrossRef286
K D Cashman, F. Branca. 2004. Phytoestrogens and the control of osteoporosis. , 115-138.
CrossRef287
Edwin M. Posadas, William L. Dahut, James Gulley. (2004) The Emerging Role of Bisphosphonates in Prostate Cancer. American Journal of Therapeutics 11:1, 60-73
CrossRef288
Alain Daragon, Sophie Pouplin. (2004) Potential benefits of intermittent bisphosphonate therapy in osteoporosis. Joint Bone Spine 71:1, 2-3
CrossRef289
Michael McClung. (2003) Use of highly potent bisphosphonates in the treatment of osteoporosis. Current Osteoporosis Reports 1:3, 116-122
CrossRef290
Cheryl D. Reich. (2003) Advances in the Treatment of Bone Metastases. Clinical Journal of Oncology Nursing 7:6, 641-646
CrossRef291
Edward C. Li, Lisa E. Davis. (2003) Zoledronic acid: A new parenteral bisphosphonate. Clinical Therapeutics 25:11, 2669-2708
CrossRef292
Lenore Buckley. (2003) Update in osteoporosis. Arthritis & Rheumatism 49:5, 732-734
CrossRef293
Ted R Mikuls. (2003) Co-morbidity in rheumatoid arthritis. Best Practice & Research Clinical Rheumatology 17:5, 729-752
CrossRef294
Richard Eastell. (2003) Management of osteoporosis due to ovarian failure. Medical and Pediatric Oncology 41:3, 222-227
CrossRef295
V Braga, D Gatti, F Colapietro, E Battaglia, D Righetti, R Prizzi, M Rossini, S Adami. (2003) Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis. Bone 33:3, 342-345
CrossRef296
Celestia S Higano. (2003) Bone loss and the evolving role of bisphosphonate therapy in prostate cancer. Urologic Oncology: Seminars and Original Investigations 21:5, 392-398
CrossRef297
Christian von Tirpitz, Max Reinshagen. (2003) Management of osteoporosis in patients with gastrointestinal diseases. European Journal of Gastroenterology & Hepatology 15:8, 869-876
CrossRef298
Juliet Compston. (2003) Osteoporosis associated with gastrointestinal diseases. European Journal of Gastroenterology & Hepatology 15:8, 841-843
CrossRef299
Henning T. Mouridsen, Carsten Rose, Angela H. Brodie, Ian E. Smith. (2003) Challenges in the endocrine management of breast cancer. The Breast 12, S2-S19
CrossRef300
David Cameron. (2003) Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies. The Breast 12, S22-S29
CrossRef301
Ian R. Reid. (2003) Bisphosphonates: new indications and methods of administration. Current Opinion in Rheumatology 15:4, 458-463
CrossRef302
David A. Bushinsky, Justin Silver. (2003) Sensing ions, secreting hormones and the structure of bone. Current Opinion in Nephrology and Hypertension 12:4, 347-348
CrossRef303
David G Little, Nicholas C Smith, Paul R Williams, Julie N Briody, Lynne E Bilston, Elisabeth J Smith, Edith M Gardiner, Christopher T Cowell. (2003) Zoledronic Acid Prevents Osteopenia and Increases Bone Strength in a Rabbit Model of Distraction Osteogenesis. Journal of Bone and Mineral Research 18:7, 1300-1307
CrossRef304
Glen S. Markowitz, Paul L. Fine, Jay I. Stack, Cheryl L. Kunis, Jai Radhakrishnan, Winicjusz Palecki, Jin Park, Samih H. Nasr, Shirley Hoh, David S. Siegel, Vivette D. D'Agati. (2003) Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney International 64:1, 281-289
CrossRef305
Theodore T. Suh, Kenneth W. Lyles. (2003) Osteoporosis considerations in the frail elderly. Current Opinion in Rheumatology 15:4, 481-486
CrossRef306
Adrian A. Bodegraven, A. Salvador Peña. (2003) Treatment of extraintestinal manifestations in inflammatory bowel disease. Current Treatment Options in Gastroenterology 6:3, 201-212
CrossRef307
M. Dror Michaelson, Matthew R. Smith. (2003) The role of bisphosphonates in the management of metastatic prostate cancer. Current Oncology Reports 5:3, 245-249
CrossRef308
MATTHEW R. SMITH, JAMES EASTHAM, DONALD M. GLEASON, DANIEL SHASHA, SIMON TCHEKMEDYIAN, NORMAN ZINNER. (2003) Randomized Controlled Trial of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer. The Journal of Urology 169:6, 2008-2012
CrossRef309
Kelly A. Mcgary, Dominick Tammaro, Michele G. Cyr. (2003) Diagnosing and managing post menopausal osteoporosis: Opportunities for fracture prevention. Comprehensive Therapy 29:2-3, 115-123
CrossRef310
Nancy A Dawson. (2003) Therapeutic benefit of bisphosphonates in the management of prostate cancer-related bone disease. Expert Opinion on Pharmacotherapy 4:5, 705-716
CrossRef311
Diane M Biskobing. (2003) Novel therapies for osteoporosis. Expert Opinion on Investigational Drugs 12:4, 611-621
CrossRef312
Jean-Jacques Body. (2003) Zoledronic acid: an advance in tumour bone disease therapy and a new hope for osteoporosis. Expert Opinion on Pharmacotherapy 4:4, 567-580
CrossRef313
Richard L Theriault. (2003) Zoledronic acid (Zometa ® ) use in bone disease. Expert Review of Anticancer Therapy 3:2, 157-165
CrossRef314
Amos Pines, Nachman Eckstein, Gideon Kopernik, Daniel Ayalon, Doron Comaneshter, Yair Frenkel. (2003) Month 3 and month 6 measurements of bone mineral density predict the annual outcome in postmenopausal women with osteoporosis in whom alendronate was added to long-term HRT. Maturitas 44:4, 287-292
CrossRef315
Michael R McClung. (2003) Bisphosphonates. Endocrinology & Metabolism Clinics of North America 32:1, 253-271
CrossRef316
(2003) Issues in Hormonal Treatment of Early Breast Cancer. Breast Cancer Research and Treatment 80:S1, 13-18
CrossRef317
Roland D Chapurlat, Pierre D Delmas. (2003) Review of ibandronate in the treatment of osteoporosis. Expert Opinion on Pharmacotherapy 4:3, 391-396
CrossRef318
Markus J. Seibel. (2003) Biochemical markers of bone remodeling. Endocrinology & Metabolism Clinics of North America 32:1, 83-113
CrossRef319
Robert E. Coleman. (2003) Current and future status of adjuvant therapy for breast cancer. Cancer 97:S3, 880-886
CrossRef320
Bastiaan R. Bloem, Janneke A.G. Steijns, Bouwien C. Smits-Engelsman. (2003) An update on falls. Current Opinion in Neurology 16:1, 15-26
CrossRef321
Matthew R. Smith. (2003) Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. Cancer 97:S3, 789-795
CrossRef322
Keri Wellington, Karen L. Goa. (2003) Zoledronic Acid. Drugs 63:4, 417-437
CrossRef323
Diane L. Chau, Steven V. Edelman, Manju Chandran. (2003) Osteoporosis and Diabetes. Current Diabetes Reports 3:1, 37-42
CrossRef324
Matthew R. Smith. (2003) Bisphosphonates to Prevent Osteoporosis in Men Receiving Androgen Deprivation Therapy for Prostate Cancer. Drugs & Aging 20:3, 175-183
CrossRef325
David Stepensky, Lilach Kleinberg, Amnon Hoffman. (2003) Bone as an Effect Compartment. Clinical Pharmacokinetics 42:10, 863-881
CrossRef326
J. E. Morley. (2003) Editorial: Hot Topics in Geriatrics. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 58:1, M30-M36
CrossRef327
Robert E. Coleman. (2002) Future Directions in the Treatment and Prevention of Bone Metastases. American Journal of Clinical Oncology 25, S32-S38
CrossRef328
Mark Clemons, Andrew Clamp, Beverley Anderson. (2002) Management of the menopause in cancer survivors. Cancer Treatment Reviews 28:6, 321-333
CrossRef329
Frank Rauch, Rose Travers, Horacio Plotkin, Francis H. Glorieux. (2002) The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. Journal of Clinical Investigation 110:9, 1293-1299
CrossRef330
Glen M. Blake, Ignac Fogelman. (2002) Bone densitometry, steroids and osteoporosis. Current Opinion in Nephrology and Hypertension 11:6, 641-647
CrossRef331
Valentina Ghinoi, Maria Luisa Brandi. (2002) Clodronate: mechanisms of action on bone remodelling and clinical use in osteometabolic disorders. Expert Opinion on Pharmacotherapy 3:11, 1643-1656
CrossRef332
Nancy A. Dawson. (2002) Bisphosphonates: their evolving role in the management of prostate cancer-related bone disease. Current Opinion in Urology 12:5, 413-418
CrossRef333
Pier Franco Conte. (2002) Bisphosphonates and Cancer: A Commentary. Clinical Breast Cancer 3:3, 217
CrossRef334
(2002) Anti-Aging Medicine LiteratureWatch. Journal of Anti-Aging Medicine 5:2, 211-230
CrossRef335
. (2002) Jaarlijkse intraveneuze toediening van zoledroninezuur bij postmenopauzale vrouwen. Medisch-Farmaceutische Mededelingen 40:8, 237-238
CrossRef336
Alan Buchman, Anthony DeSantis. (2002) Current and emerging therapies in osteoporosis. Expert Opinion on Pharmacotherapy 3:7, 835-84
CrossRef337
Sheila A Doggrell. (2002) Zoledronate once-yearly increases bone mineral density – implications for osteoporosis. Expert Opinion on Pharmacotherapy 3:7, 1007-1009
CrossRef338
Diane M. Biskobing, Angela M. Novy, Robert Downs. (2002) Novel therapeutic options for osteoporosis. Current Opinion in Rheumatology 14:4, 447-452
CrossRef339
(2002) Bisphosphonates and Osteoporosis. New England Journal of Medicine 346:26, 2088-2089
Full Text340
Ian R Reid. (2002) Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety. Expert Opinion on Drug Safety 1:1, 93-107
CrossRef341
Solomon, Caren G., . (2002) Bisphosphonates and Osteoporosis. New England Journal of Medicine 346:9, 642-642
Full Text342
S. E. Papapoulos. (2001) Yearly Bisphosphonate Infusions for the Management of Osteoporosis?. International Bone and Mineral Society Knowledge Environment 1:1, 2002035-0
CrossRef343
M. J. Rogers. (2001) Meeting Report from What is New in Bisphosphonates: Sixth Workshop on Bisphosphonates. International Bone and Mineral Society Knowledge Environment 1:1, 2002041-0
CrossRef
- Letters
